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1.1 Gene therapy 
 
 
Gene therapy has been widely associated for the treatment of a wide range of gene anomaly 
associated diseases such as cancer, autoimmune diseases and neurodegenerative diseases [1]. 
Gene therapy is based on introducing the genetic cargo into the target tissues and thus 
inhibiting or altering the expression of endogenous genes in order to prevent the spread of the 
disease. The progression in the field of cancer gene therapy has revealed abundant potential 
for various forms of treatment. Various in vivo and in vitro therapetic strategies have shown 
remarkable results such as in case of lung cancer, gene therapy application to create cancer 
vaccines, introducing viruses into tumors in order to cause lysis followed by cell death or 
instigating genes into cancer cells causing either cell death or restoration of normal cellular 
functions and phenotype [2]. 
 
The initial hype and enthusiasm for this revolutionary field of gene therapy is however taken 
a turn towards more cautious therapeutic approaches after realisation of the associated risks 
and setbacks such as death of a patient taking part in a dose escalation gene therapy trial in 
1999 [3]. Although this incident was not related to cancer treatment but a metabolic disorder 
(ornithine transcarbamylase deficiency), this led to re-evaluation of all gene therapy trials for 
safety. A lot of new practices were incorporated and thousands of patients took part in clinical 
trials of cancer gene therapy and showed eminently fewer adverse effects as compared to the 
side effects observed with traditional chemotherapy [4].  
 
Gene delivery vehicles play a major part to initiate a potential adverse effect and most of these 
adverse effects are observed because of viral vectors such as immunogenicity and higher 
cytotoxicity. The first reported gene therapy clinical trial fatality was related to inflammatory 
reaction because of Adenovirus which was used as a viral vector for gene delivery [5]. Thus 
non-viral vectors are deemed more safe to use although there are challenges for efficient 
transfection because of intracellular and extracellular barriers. However, lesser pathogenicity, 
ease of production and cost-effictiveness are the characteristics which make non-viral vectors 
better candidates for gene delivery than viral vectors [6]. Non-viral vectors for gene therapy 
include naked plasmids, chemical based and particle based. The major aspects which need to 
be thoroughly investigated before selection of a non-viral vector for gene therapy are: the 




immune response, activity, regulative concerns, ethical considerations and commercialization 
[7, 8]. 
 
1.2 Nanocarriers for gene therapy 
 
 
Nanoparticles are believed to be the most promising gene delivery vehicles because of their 
shape, tunable size, surface characteristics and biological behavior [9]. Nanocarriers possess 
cationic surfaces which provide facilitation to encapsulate anionic nucleic acids cargo for 
intracellular delivery [10]. These cationic nanocarriers include cationic liposomes, micelles, 
polymers, hydrospheres and hydrogels etc. which have been investigated extensively for their 
potential as gene delivery systems. However, most of clinical trials until present involve 
cationic liposomes as gene delivery vehicles for their efficacy and safety for plasmids as well 
as small interfering RNA [11].  Among recent studies on nanocarriers, lipopolyplex has 
emerged as a very promising non-viral vector for gene therapy because of its exceptional 
colloidal sustainability,  marginal cytotoxicity and exceeding transfection efficiency [12]. 
Lipopolyplex is designed as a second generation non-viral nucleic acid vector comprised of 
liposome and polyplex following the first generation liposome-DNA complex [12, 13]. 
 










In previous studies, polyethylenimine (PEI) has been found an efficient nucleic acid vehicle 
both in vitro as well as in vivo [15] because of its high nucleic acids compaction ability and 
innate endosomolytic capacity [16]. Polyplexes are the complexes or composite aggregates 
of nucleic acids with cationic polymers, which in our studies are plasmid DNA or siRNA and 
lPEI [14]. The lPEI is deacylated PEI which is an improved version of linear PEI because 
after deacylation, its transfection efficiency is remarkably increased and cytotoxicity is 
significantly decreased because of lack of primary amines which are frequently present in 
branched PEI causing high charge density leading to compromised cell wall integrity causing 
cellular necrosis [17].  These polyplexes, containing nucleic acid and lPEI, often induce 
immune responses because of their overall cationic nature [18]. To address this problem, these 
polyplexes were wrapped with liposomes composed of DPPC, DOPE and cholesterol.  
 
DPPC: Dipalmitoylphosphatidylcholine contains a fatty acid polar phosphate head group 
along with a nonpolar chain of fatty acid. DPPC molecules can arrange according to polar and 
nonpolar interactions with a phospholipid bilayer forming spherical vesicles [19]. 
DOPE: Dioleoylphosphoethanolamine is a non-bilayer synthetic, unsaturated, conical 
phospholipid. DOPE arranges into hexagonal inverted phase because of its negative 
spontaneous curvature [20]. Cholesterol: Cholesterol is a single polar hydroxyl group 
lipophilic molecule. Cholesterol stabilises liposomes and bio-membranes by providing 
mechanical compactness and elasticity. Moreover, it enhances phosphatidylcholine vesicle 
resistance and deters vesicle aggregation [21]. 
`  
1.3 siRNA mediated gene therapy for cancer treatment 
 
 
The phenomenon of RNA interference in animals was first reported in 1998 when Fire et al 
found that a complementary double stranded RNA can act as a gene silencer in Caenorhabditis 
elegans [22]. Initial observation of gene silencing in plants was reported in early 90’s and 
expressed the same pattern of gene silencing by transcript-dependent endonucleolytic 
breakdown of mRNA [23]. RNA silencing is defined as post-transcriptional inhibition of gene 
expression by silencing mRNA [24]. RNA interference is believed to be a promising substitue 
for convetional cancer therapies being less cytotoxic than traditionally used chemotherapy. 




diseases, genetic abnormalities, cardiovascular conditions, viral infections as well as cancers. 
The potentiality to target any gene is the most appealing characteristic of siRNA treatment 







Figure 2: Graphical representation of siRNA induced mRNA inhibition 
 
Gene silencing by siRNA knockdown has revolutionized molecular and cell biology studies. 
The basic mechanism of action of siRNA mediated gene silencing involves instigation of 
impairment in complimentary strand of mRNA by neutralizing it thus rendering its use as a 
translation template [26, 27]. This is achieved by exogenous introduction of small interfering 




helps a template of siRNA to locate and target the complementary mRNA resulting in the 
cleavage of mRNA by a ribonuclease. Thus mRNA becomes unattainable for the translation 
process and thereby causes inhibition of protein expression [28-31]. siRNA has the potential 
to treat not only cancers but also infectious diseases and disorders that originate from genetic 
disorders or mutations. siRNA mediated gene knockdown has become a standard tool for 
molecular targeting therapy [27, 32]. 
 
    1.4    Transfection of siRNA into cells 
 
 
siRNA can be introduced into eukaryotic cells either by a viral or non-viral delivery vehicle. 
Viral transfection, also known as transduction, has been widely used in clinical research 
because of  high transfection efficiency and persistent transgene expressions [33].  Most 
common viruses used for this purpose are Lentivirus, Adenovirus, Retrovirus and Adeno-
associated virus etc. However the drawbacks such as mutagenesis, cytopathic changes and 
high costs of using viral transfection limit their use [34].  
 
Non-viral techniques of transfection include either chemical methods usually invloving 
nanoparticles, lipofection, polymeric carriers of genetic material: polyplexes etc. [35]  or 
physical methods such as direct micro injection, electroporation, magnetofection, cell 
squeezing etc. Transfection of genetic material into cells can be achieved with the goal of 
transient or stable transfection [36-38].  
 
Stable transfection results in the integration of transfected genetic material into the host 
genome and also inheritance of this genetic material by the daughter cells, thus causing that 
cell line to express altered characteristics of introduced genetic material permanently.  
Transient Transfection, on the other hand, results in temporary introduction of foreign genetic 
material into a cell, where it does not become part of the host genome and is diluted out after 
cell division over time resulting in the loss of expression of the transfected gene [39].
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1.5     Head and neck squamous cell carcinoma 
 
 
Head and neck squamous cell carcinoma (HNSCC) affects more than 800,000 patients every 
year, representing the 6th most common cancer world-wide [40, 41]. Standard treatment 
strategies for HNSCC involve surgery, radiation, chemotherapy or a combination of all these 
but these options are still incapable of decreasing the mortality rate significantly [42]. To 
improve rather scant outcome of therapies which are in practice for HNSCC, molecular-
targeting approaches have given a new direction to further therapeutic options [43]. 
Molecular therapies against cancers focus on targeting specific molecules responsible for 
cancer development, advancement and metastasis [44] instead of assaulting all cells 
indistinctively  (as in conventional chemotherapy).  
 
All of neoplastic diseases emerge from five mutual traits [45] which are: 
Impeccable continuation of proliferative signalling 
Eluding growth suppressors 
Combating cell death 
Facilitating replicative immortality 
Commencing angiogenesis, boosting up invasion and metastasis 
 
 Targeted molecular therapy techniques against cancers specifically prey one or more of the 
regulatory factors controlling above mentioned mechanisms which are responsible for 
various stages of a tumour formation. For in vivo testing of anti-viral therapies for treatment 
of HPV induced carcinomas such as HNSCC, the only available models are 
immunocompromised mice and human tissue xenografts [46]. The basic drawback of this 
model system is the lack of natural host system during development of papilloma [47].  
 
 1.6     Parallel pattern of HPV and CRPV induced carcinomas 
 
 
As this study is based on the comparison of parallel efficacies of HPV E6 and E7 
oncoproteins with CRPV E6 and E7 oncoproteins, so it is important to understand the role of 
former mentioned genes to grasp the mode of action of the CRPV oncogenes.   
Two major types of  oncoproteins are encoded by HPV, E6 and E7, which are directly 
accountable for HPV carcinome progression [48, 49]. These HPV oncogenes work side by 
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side to target various cellular pathways responsible for cell cycle regulation, apoptosis and 
controlling mechanisms of cell polarity [50-52].  
 
1.7   Role of HPV E6 and E7 oncogenes 
 
 
Human Papilloma Virus has five species: (α) alpha, (β) beta, (γ) gamma, mu and nu papilloma 
viruses [53]. Among these, α and β are found the most intensively infectious types. Alpha 
HPV types are divided into low risk, LR, and high risk, HR types [54, 55]. Low risk α type 
HPV-6 and 11 usually cause benign lesions whereas high risk α type HPV-16 and 18 are 
responsible for malignant cancers in ano-genital and head and neck areas [56]. In case of 
HPV associated head and neck carcinomas, which assault oropharynx, HPV-16 is the most 
frequent cause worldwide [57, 58].  
 
Αlpha-HPV species infect the mucosal epithelial layer by infiltrating through micro-bruises 
or mild lesions. As virus cannot reproduce by itself, so it exploits cellular epithelial 
differentiation processes to replicate and in this process HPV E6 and E7 play a vital role. 
These viral genes sabotage cell cycle regulation and apoptosis in cells of the basal layers that 
results in very high viral copy number and tumor formation [59, 60]. In case of some 
persistent infections, viral DNA somehow integrates into host genome, causing loss of viral 
proliferation ability and most of viral genes except E6 and E7 oncogenes which are 
uncontrollably expressed and cause immortalization of cells resulting in the development of 
malignancies [61, 62]. 
 
HPV E6 and E7 oncogenes, when expressed in combination, cause immortalization of cell 
lines derived from tumors as E6 compromises cellular survival pathways while E7 promotes 
cells proliferation [63]. However, when these genes are expressed individually, they do not 
result in dramatic effects on immortalization of cells and fail to induce neoplasm or 
carcinoma in spite of the fact that E6 causes elevated copies of centrosomes and abolishes 
traceable levels of p53 protein whereas E7 results in higher number of centrosomes and 
elevated proliferation [64]. In case of HNSCC, E7 oncoprotein is found to be the main 
transforming factor while E6 is considered to play a vital role in later stages of tumor 
development [65].  
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1.8    Role of CRPV E6 and E7 oncogenes 
 
 
CRPV E6 and E7, without any other co-factors, are found to immortalize rabbit keratinocytes 
in vitro and this ability to proliferate cells uncontrollably is also a characteristic of HPV E6 
and E7 oncogenes which is believed to be a prerequisite in the formation of all HPV cancers 
[66]. Cottontail rabbit papilloma virus animal model is used extensively for therapeutic 
investigations of HPV associated carcinomas because both of these models have parallel 
efficacy and resemblance in papilloma virus-induced cancers progression [67].  
 
Various reports have been published about downregulation of HPV E6 and E7 ocnogenes 
either directly, by siRNA silencing or indirectly, by inhibition of various cancer markers and 
their consequent effect on tumor growth and cell proliferation markers [68-70]. These studies 
have well established the role of HPV E6 and E7 genes to offset p53 and Rb tumor suppressor 
pathways respectively. Interestingly, no current information is available on siRNA silencing 
of CRPV E6 and E7 oncogenes. CRPV generates three proteins, CRPV LE6, SE6 and CRPV 
E7 which are responsible for anchor independent proliferation in immortalized cell lines [71].  
 
CRPV E6 proteins, unlike HPV E6, have been found to be unable to bind with and thus 
inhibit p53 in mouse embryonic carcinoma cells [72] which indicates that in spite of having 
almost similar charactersitics as HPV E6, CRPV E6 proteins also show some contrasting 
traits as it is important to take into consideration both similar as well as opposite factors while 
comparing two parallel treatment strategies. However, CRPV E7 protein has analogous 
characteristics as HPV16 E7 such as binding to pRb, inhibition of complex formation 
between pRb and the E2F transcription factor, transactivation of adenovirus E2 promotor and 
facilitating the cellular transformation in rodent fibroblasts as determined by growth in soft 
agar [73].  
 
CRPV E7 is also shown to immortalize rabbit keratinocytes in the absence of mitogenic 
stimuli by decreasing rabbit p19ARF which inhibits ubiquitin ligase activity resulting in an 
increase in the p53 protein half-life. However, this accomplice for p53 does not ffect on cells 
proliferation. CRPV E6 does not bind to p53 unlike high risk HPV E6 proteins and even after 
proteasomal inhibition, p53 remains active on transcriptional level and induces p21 [56].  
How CRPV and low risk cutaneous and genital HPV carcinomas, inspite of  their inability 
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of E6 proteins to bind to p53, still manage to escape p53-mediated growth arrest, is not 
answered yet [56].  
 
Several groups have discussed the importance of CRPV E1, E2, E6 and E7 proteins to induce 
papilloma formation in rabbits. So it is well established that all of these CRPV early genes 
provide possible targets for molecular targeting strategies to treat CRPV associated 
carcinomas [74, 75].  
 
1.9    In-vitro system for therapeutic evaluation of Papilloma 
virus induced cancers 
 
 
The parallel efficacy of therapeutic strategies to treat CRPV induced carcinomas in cottontail 
rabbit versus treatments used for HPV associated cancers, has been previously established in 
different clinical settings [76, 77]. The CRPV rabbit model system provides a remarkable 
foundation to investigate a wide range of antiviral therapies in vivo.  
 
The analogous pattern of growth of CRPV-induced carcinoma and HPV associated cancers 
makes the cottontail rabbit model a promising candidate to explore various in vivo treatments 
[78, 79]. However, the major limitation of this model is the variability in immunocompetent 
rabbits to respond to CRPV infection and treatments thus increasing the cost of investigating 
therapeutic compounds quite significantly [76]. Hence an in vitro system is essential to study 
different therapeutic approaches for the treatment of papilloma virus dependent carcinomas. 
Various publications reporting the establishment of CRPV+ VX2 carcinoma cell lines have 
appeared previously over the years [80-83], however, none of these cell lines was available 
commercially for investigative purposes, so in a different study, we have developed a CRPV 
carcinoma derived VX2 cell line which has been characterized extensively and here we use 
this VX2 cell line to apply gene therapy techniques to treat CRPV carcinoma. 
 
Transient Transfection, on the other hand, results in temporary introduction of foreign genetic 
material into a cell, where it does not become part of the host genome and is diluted out after 
cell division over time resulting in the loss of expression of the transfected gene [39]. In this 
study, we used transient transfection as a source to introduce genetic material or siRNA into 
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cells. Here lipopolyplexes were used as transfecting reagents. 
 
1.10    Effect of stress inducing factors on oncogenic expressions 
 
 
 1.10.1   Serum starvation 
 
Previous studies have shown cancer cells exhibiting resistance to serum starvation or 
nutrients depletion. For example, in case of breast cancer, Gli1, an activator of the hedgehog 
(Hh) signalling pathway and being involved in cell survival and cancer growth, is up-
regulated in serum starved cancer cells [84]. 
 
In several studies, serum starved LoVo colon cancer cells showed alterations in ADMA level 
and also significant transcriptional fluctuations of genes involved in apoptosis, cell cycle, 
p53 signalling pathway and nucleic acids metabolism [85] .  
 
Chinese Hamster lung fibroblasts, V79, are adherent cells and grow in monolayer in serum 
enriched medium but when exposed to serum starvation, start rounding up and cause 
upregulation of p53 and PKC-α proteins. An extended period of serum starvation (≥48h) may 
lead to cell detachment and death in v79 cells [86].  
 
In human colorectal cancer cell lines such as HCT 116 and breast cancer cells cultured in 
scarce-nutrient situations express higher levels of p21, independent of any relation to p53, 
which causes p21 to save cells from serum depletion induced apoptosis and cell death [87].  
 
 1.10.2   Effect of cisplatin treatment on cancer cells 
 
Serum starvation of non-cancerous cells causes growth arrest and indifferent response 
towards cisplatin toxicity whereas in case of cancer cells, mild effect on proliferation rate 
and significant susceptibility for cisplatin toxicity because of activation of ATM/Chk2/p53 
signalling pathway is observed under serum deprivation conditions [88]. Cisplatin exposure 
alone can cause significant alterations in transcriptional levels of different genes such as 
GJA1 and TWIST1 involved in early development of cells and cell to cell communication. P53 
levels are also found to be amplified after exposure to higher doses of cisplatin in both drug 
sensitive and drug resistant cancer cells [89]. 
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In ovarian cancer cell lines, Cisplatin treatment has shown to cause down-regulation of 
MCTP1 and up-regulation of S100A3 and C4orf18 genes which offer major resistance to 
cancer cells against cisplatin. Cisplatin induced variations in expression of various genes can 
lead to therapeutic solutions involving targeting these differently expressed genes and 
reversing drug resistance in cancer cells [90].  
 
 1.10.3   Effect of radiation on cancer cells 
 
Oncogenes exhibit a change in usual pattern of transcriptional levels after radiation in both 
normal tissues and cancer cells [91, 92]. When wild type  C57BL/6 mice was exposed to 
high-photon based and charged particles radiation, magnified expression of 78 oncogenes 
was observed in liver tissues whereas 88 oncogenes were expressed differently in mouse 
spleen, lungs, brain, kidneys, liver as well as in small and large intestines post HZE 56Fe 
particle radiation [93].  
 
Other studies have demonstrated fluctuation of gene expression profiles after radiation, some 
of which depend upon type of cell line while few special genes are found to be associated 
with high resistance status of cancer cells [94, 95]. 
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Aims and Objectives 
 
The primary purpose of this work was to determine the versatility of lipopolyplexes as non-
viral vectors for gene therapy and establishing non-conventional techniques to evaluate their 
transfection potential in different cell lines. Another goal of this study was to fill the space 
between parallel therapeutic options regarding HPV and CRPV induced cancers as both of 
these carcinomas originate from closely related set of oncogenes.   For this purpose, CRPV 
E6 and E7 oncogenes were targeted by siRNA and downregulation of their gene expressions 
was monitored by different scientific assays.  
 
The key elements of this study include: 
 
1. Preparation of pre-designed lipopolyplexes and affirmation of their physicochemical 
characteristics 
2. Determination of transfection efficiency of lipopolyplexes in VX2 and COS-7 cells 
3. Evaluation of cytotoxicity of lipopolyplexes in VX2 and COS-7 cells 
4. Detection of CRPV E6 and E7 transcripts in VX2 cells 
5. Knockdown of CRPV E6 and E7 oncogenes in VX2 cells by using siRNA loaded 
lipopolyplexes 
6. Designing a parallel system for evaluation of siRNA efficiency to downregulate 
CRPV E6 and E7 oncogenes in the absence of a VX2 cell line  
-Transfection of GFP tagged CRPV E6 and E7 oncogenes in COS-7 cells followed 
by siRNA mediated knockdown 
 -siRNA-mediated downregulation of CRPV E6 and E7 oncogenes in VX2 tumor 
suspension  
7. A detailed account of limiting factors affecting gene therapy of CRPV carcinoma 













Part II: Experimental 
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2.1     Materials and instruments 
 
Instruments and Materials Sources 
0.2 µmol/L PES Syringe Filters Whatman plc, Buckinghamshire, UK 
0.2µmol/L non-Pyrogenic Filters Schleicher and Schuell, Dassel, Germany 
12-well plates; Nunclon Delta Nunc GmbH and Co. KG., Wiesbaden, Germany 
96-well Microtiter Plates; CytoOne® Starlab International GmbH, Hamburg, Germany 
Adhesive Plate Seals 
Boehringer Mannheim GmbH, Mannheim, 
Germany 
Amphotericin B Biochrom, Berlin, Germany 
Ampicillin Sigma Aldrich, St. Louis, MO, USA 
Ampicillin 
Sigma Aldrich Chemie GmbH, Taufkirchen, 
Germany 
Autoradiography Cassette Agfa, Köln, Germany 
Bath Sonicator; Transonic Digital S Elma Schmidbauer GmbH, Singen, Germany 
BD FACS Calibur Flow Cytometer Becton Dickinson, Heidelberg 
Bradford Spectrophotometer Hamburg, Germany 
Cell Culture Hood (work bench) Heraeus, Hanau 
Cell Culture Lysis Reagent Promega GmbH, Mannheim, Germany 
Centrifuge 5430R Naumburg, Germany 
Centrifuge 5920R Naumburg, Germany 
Chloroform Roth, Kalsruhe, Germany 
Cholesterol 
Sigma Aldrich Chemie GmbH, Taufkirchen, 
Germany 
Cisplatin 
Sigma Aldrich Chemie GmbH, Taufkirchen, 
Germany 
Confocal Laser Scanning Microscope; 
LSM 510/Axiovert 100M 
Carl Zeiss Microscopy GmbH, Jena, Germany 
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Culture Tubes; Pyrex Corning Inc., Corning, USA 
DAPI 
Sigma Aldrich Chemie GmbH, Taufkirchen, 
Germany 
DMEM PAA Laboratories, Pasching, Austria 
DMEM Lonza GmbH, Walkerville, MD, USA 
DMEM: F-12 Capricorn, Ebsdorfergrund, Germany 
DMEM-LG Biochrom GmbH, Berlin, Germany 
DMSO (≥ 99 %) Acros Organics B.V.B.A., Geel, Belgium 
DNA Ladder; Gene Ruler 1 kb Fermentas Life Sciences, Vilnius, Lithuania 
DOPE Lipoid GmbH, Ludwigshafen, Germany 
DPPC Lipoid GmbH, Ludwigshafen, Germany 
Dulbecco’s Phosphate-Buffered Saline 
PBS 
Biochrom AG, Berlin, Germany 
EDTA Roth, Karlsruhe, Germany 
Epithelial Volt-Ohmmeter for TEER WPI, Sarasota, FL, USA 
E-Plate for xCELLigence System Roche, Mannheim, Germany 
Eppendorf Bio Photometer Eppendorf-Netheler-Hinz, Hamburg, Germany 
Ethanol Roth, Karsruhe, Germany 
Ethanol 
Carl Roth GmbH + Co. KG., Karlsruhe, 
Germany 
Ethidium Bromide 
Sigma Aldrich Chemie GmbH, Taufkirchen, 
Germany 
Ethidium Bromide 1% Roth, Karlsruhe, Germany 
Extruder; Avanti Mini Avanti Polar Lipids Inc., Alabaster, USA 
Fetal Bovine Serum 
Sigma Aldrich Chemie GmbH, Taufkirchen, 
Germany 
Fluorescent Mounting Medium Dako Cytomation , Carpinteria, CA, USA 
Foetal Bovine Serum PAA Laboratories GmbH, Cölbe, Germany 
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Freezer (-30°C) PORRKA, Hollola, Finland 
Freezer (-86°C) Sanyo, Bad Neudorf 
Gel Doc 2000 
Bio-Rad Laboratories GmbH, München, 
Germany 
Gentamycin Biochrom, Berlin, Germany 
Glycerol Roth, Karlsruhe, Germany 
Hot Block for Tubes HCL HBT 130, Kobe, Japan 
Hydrochloride Acid Merck, Darmstadt, Germany 
Ice Machine Ziegra, Isernhagen 
Incubator Shaker New Brunswick Scientific,USA 
Isopropanol Acros Organics, NJ, USA 
Laminar Flow Hood; Labgard Class II NuAire Inc., Plymouth, USA 
Laser Scanning Microscope Olympus, Hamburg 
Leica Microsystems Wetzler, Germany 
Lipofectamine TM 2000 Thermofischer Scientific, UK 
Liquid Blocker Daido, Sangyo, Japan 
Magnetic Stirrer; MCS 66 CAT Scientific, Paso Robles, USA 
Medical X-ray film Agfa-Gevaert, Mortsel, Belgium 
Methanol Sigma-Aldrich, St. Louis, MO, USA 
Micro Reagent Tubes Sarstedt AG and Co., Nümbrecht, Germany 
Microscope (Olympus A×70) Olympus, Hamburg 
Microscopy Slides 
Gerhard Menzel B.V. and Co. KG., 
Braunschweig, Germany 
MilliQ® Water Millipore Corporation, Billerica, USA 
Mini Electrophoresis System Bio-Rad, Hercules, CA, USA 
Mini Protean II Dual Slab Cell Bio-Rad, Hercules, CA, USA 
Mounting Medium; FluorSave™ Calbiochem Corporation, San Diego, USA 
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MTT (Thiazolyl Blue Tetrazolium 
Bromide) 
Sigma Aldrich Chemie GmbH,  Taufkirchen, 
Germany 
Nitrocellulose Membrane Schleicher-Schuell Biosci., Dassel 
Nonidet P40 Substitute NP40 Sigma-Aldrich, St. Louis, MO, USA 
Olaparib Thermofischer Scientific, UK 
Optimax X-ray Film Processor Oberstenfeld, Germany 
Penicillin/ Streptomycin Capricorn, Ebsdorfergrund, Germany 
PEI MAX; Linear PEI 22 kDa 
Polysciences Europe GmbH, Hirschberg, 
Germany 
Petri Dishes; Tissue Culture grade and 
Suspension type 
Sarstedt AG and Co., Nümbrecht, Germany 
Pipetman Gilson, Middleton, WI, USA 
Pipetting Aid Hirschmann, Eberstadt, Germany 
Polycarbonate Membranes Whatman plc, Buckinghamshire, UK 
Polymin®; Branched PEI 25 kDa BASF AG, Ludwigshafen, Germany 
PowerUp SYBR Green Master Mix Applied Biosystems, Fisher Scientific, UK 
Precision Plus Protein All Blue 
Standards 
Bio-Rad Laboratories, München 
Quantstudio 5 RT qPCR instrument Applied Biosystems, USA 
Ribonuclease A Sigma-Aldrich, St. Louis, MO, USA 
RNAse free water 
GE Healthcare Europe GmbH, Freiburg, 
Germany 
Rotary Evaporator; Laborota 4000 
Heidolph Instruments GmbH and Co. KG., 
 Schwabach, Germany 
Rotiphorese Gel 30 Roth, Karlsruhe, Germany 
Shaking Incubator; IKA KS4000 IC IKA Werke and Co. KG., Staufen, Germany 
siRNA Dilution Buffer 
GE Healthcare Europe GmbH, Freiburg, 
Germany 
Skim milk powder Merck, Darmstadt, Germany 
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Sodium Chloride Merck, Darmstadt, Germany 
Sodium Hydroxide  Fisher Scientific, Leicestershire, UK 
Sodium Dodecylsulfate Serva Electrophoresis, Heidelberg, Germany 
Tetramethylethylenediamine, TEMED Roth, Karlsruhe, Germany 
Thermal Printer DPU 414 Eppendorf, NY, USA 
Thermocycler Biometra, Göttingen, Germany 
Thin-Certs (0.4µmol/L) Greiner Bio-One, Frickenhausen 
Tris-HCL  Roth, Karlsruhe, Germany 
Triton™ X-100 
Sigma Aldrich Chemie GmbH, Taufkirchen, 
Germany 
Trypsin-EDTA PAA, Laboratories, Pasching, Austria 
Ultraviolet Transilluminator UVP, Upland, CA, USA 
xCELLigence Roche, Mannheim 
X-ray film Agfa, Motsel, Belgium 
 
2.1.1   siRNA sequences 
  (Dharmacon Inc, USA) 
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2.1.2   Oligo primers 
 (Invitrogen, Thermofischer Scientific, Germany) 
 
 














Forward 5‘-GAAGCTGCTGCCTCATATCC -3‘ 








Forward 5‘-CGGAAACCCAGAGGTATTGA -3‘ 
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2.1.3   Cell lines 
 
1. African Green Monkey SV40-transformed kidney fibroblast cell line (COS-7) 
 




2.1.4   Kits 
 
1. First strand cDNA-Synthesis Kit (Roche Diagnostics, Mannheim) 
 
2. QIAgen RNeasy Mini Kit (Qiagen, Hilden) 
 
2.1.5   Antibodies 
 
 2.1.5.1      Primary antibodies 
 
 
1. Anti-GFP (Santa Cruz Biotechnology, Santa Cruz, CA, USA) 
 
2. Anti-PCNA (Santa Cruz Biotechnology, Santa Cruz, CA, USA) 
 
3. Anti- Tubulin (Santa Cruz Biotechnology, Santa Cruz, CA, USA) 
 




2.1.5.2 Secondary antibodies 
 
 
1. Anti-mouse-IgG, HRP-linked antibody (Santa Cruz Biotechnology, Santa Cruz, 
CA, USA) 
 














Liposomes, Polyplexes and Lipopolyplexes 
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As most of the physicochemical, complex stability as well as surface, morphological and 
structural characteristics of these liposomes, polyplexes and lipopolyplexes have been 
previously established [14], the main focus of this study is to elucidate the cellular uptake 
and cytotoxicty traits of lipopolyplexes in VX2 and COS-7 cells in which they have not been 
used as transfecting reagents previously. 
 
 2.2.1   Preparation of liposomes 
 
Liposomes, polyplexes and lipopolyplexes were prepared by a previously established method 
[73]. Briefly, Lipids including DOPE (1,2-Dioleoyl-sn-glycero-3-phosphoethanolamine),  
DPPC (1,2-Dipalmitoyl-sn-glycero-3-phosphocholine) and cholesterol, in a proportion of 
(70:15:15) respectively, were dissolved in 2 ml of 2:1 (v/v) chloroform: methanol  solution 
in a 5 ml round bottom flask. Once dissolved, they were evaporated at 40°C on a 
rotary evaporator (Laborota 4000) supplied with a vacuum pump, to obtain a thin film. 10 
mM HEPES buffer (pH 7.4) was used to hydrate the lipid film by sonication in a bath 
sonicator to obtain homogeneous suspension of liposomes. For further size reduction, these 
liposomes were extruded 21 times from Avanti Mini Extruder by using 
polycarbonate membranes (Whatman) of 400 nm and 200 nm pore size respectively. Finally, 
the liposomes were filtered through 0.2 μm syringe filters. 
 
 2.2.2   Preparation of polyplexes 
 
Polyplexes were prepared with N/P ratio (ratio of PEI nitrogen atoms to nucleic acid 
phosphate atoms) of 9.5. lPEI was diluted in 10 mM HEPES buffer and pipetted into 1.5 ml 
Eppendorf tubes containing equal volume of DNA (diluted in Optima serum-free medium) 
or siRNA (diluted in 1x siRNA dilution buffer) and incubated at room temperature for 20-
25min under a laminar airflow hood.  
 
 2.2.3   Preparation of lipopolyplexes 
 
For preparation of lipopolyplexes, liposome to PEI mass ratio (0.39:1) was used and 
accordingly calculated amounts of liposomes and polyplexes were vigorously mixed in an 
Eppendorf tube by pipetting. Complexes were incubated at room temperature for 1 h under a 
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laminar airflow hood and resulting lipopolyplexes were used for transfection by mixing with 
cell culture medium on the cells. 
 
 2.2.4   Physicochemical characteristics 
 
 
2.2.4.1      Dynamic light scattering 
 
The size of liposomes, polyplexes and lipopolyplexes was determined using a Zetasizer Nano 
ZS (Malvern Instruments) instrument by dynamic light scattering. Clear disposable capillary 
cells (DTS1060; Malvern Instruments) were used for this purpose. For size analysis, 
liposomes, polyplexes and lipopolyplexes were diluted with 10 mM HEPES (pH 7.4) in a 
ratio of 1:100, 1:20 and 1:20 respectively. Measurements were carried out at a detection angle 
173º backscatter and a wavelength of 633 nm. Laser attenuation as well as measurement 
position were adjusted by the instrument automatically according to the sample. Instrument 
worked with 15 size runs each lasting 10 s for each measurement. For data analysis, refractive 
index and viscosity of water at room temperature were considered as 1.33 and 0.88 mPa.s 
respectively. Three independent formulations were analysed and an average of their diameter 
was calculted.  
 
 2.2.5   Maintenance of cell culture 
 
VX2 cells were cultivated at 37ºC and 5 % CO2 in humid conditions in DMEM/ HAM`S F-
12 medium supplemented with 10 % foetal calf serum and 100 U/ml Penicillin, 100 mg/ml 
Streptomycin, 50 μg/ml gentamicin, and 100 μg/ml Amphotericin. COS-7 cells [96] were 
cultivated at 37ºC and 5 % CO2 in humid conditions in DMEM medium supplemented with 
10 % foetal bovine serum along with 100 U/ml Penicillin, 100 mg/ml Streptomycin, 50 μg/ml 
gentamicin and 100 μg/ml Amphotericin. Both cell lines were grown in 100 mm tissue 
culture dishes and passaged after reaching to 80 % confluency. 
 
 2.2.6   Cellular uptake of lipopolyplexes 
 
For plasmid transfection, cells were grown on 6-well plates (1x104 cells per well) for 24 h 
until reaching to 60 % confluency. Prior to transfection, the medium on the cells was changed 
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to 900 µl of serum free DMEM/ HAM`S F-12 and serum free DMEM for VX2 cells and 
COS-7 cells respectively. VX2 and COS-7 cells were transfected with lipopolyplexes 
containing 2 μg plasmid DNA (E7_GFP) in a volume of 100µl Optimum serum-free media. 
Cells were left incubating for 4 h before adding 1ml additional media (with serum and 
antibiotics). One well from each plate was transfected with LipofectamineTM2000 using 2 μg 
control plasmid DNA (E7_GFP) according to manufacturer’s protocol (Table 1), serving as 
a positive control for transfection experiments. 
 
Table 1. Concentrations of LipofectaminTM 2000, dilution medium and plasmid for 
transfection into various types of cell culture plates 



















LipofectaminTM    
2000 (μl) 
 
12 well 4 1 2X100 1.6 4 
6 well 10 2 2X250 4.0 10 
60 mm 20 5 2X500 8.0 20 
 
Untreated cells were used as negative control.  The transfected cells were incubated for 48 h. 
Afterwards, cells were trypsinized and resultant cell pellets were re-suspended in 1 ml PBS 
(pH 7.4). 500 µl of the cell suspension was again centrifuged to obtain a cell pellet for RNA 
extraction (qPCR) and the remaining 500 µl cell suspension was saved for flow cytometry in 
FACS tubes. One ml of ice-cold ethanol was added dropwise to each FACS tube containing 
cell suspension, while being vortexed and stored at 4°C until FACS analysis. 
 
 2.2.7   RNA extraction and quantification 
 
Total RNA was extracted from VX2 and COS-7 cells using the RNeasy Mini kit (Qiagen, 
Germany) according to the manufacturer’s protocol. Total RNA concentration was measured 
on NanoDrop ND-1000 (peqLab Biotechnologie GmbH) at an extinction range of 260 nm. 
Also, the OD 260/230 and the OD 260/280 ratio demonstrating RNA purity were assessed. 
All measurements were taken as triplicates. 
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 2.2.8   Reverse transcription 
 
cDNA was prepared by using 500 ng of total RNA for each sample deploying the 
Transcriptor First strand cDNA synthesis kit (Roche, Mannheim, Germany) according to 
manufacturer’s protocol. Briefly, 500 ng of total RNA was diluted with RNase free water to 
12 µl followed by adding 1 µl of Oligo (dT) primer (500 mg/ml) in 0.5 ml RNase-free 
Eppendorf tubes which were then placed inside a thermocycler (TProfessional Thermocycler 
Biometra, Gottingen, Germany). The RT mix was heated to 65°C for 10 min, cooled on ice 
followed by addition of a master mix (4 µl of first-strand buffer 5X, 0.5 µl Protector RNase 
Inhibitor, 2 µl Deoxynucleotide mix and 0.5 µl Transcriptor Reverse Transcriptase). A final 
volume of 20 µl of RT mix was incubated at 50°C for 60 min followed by 85°C for 5min and 
4°C hold. After cDNA preparation, all samples were diluted 2-fold with RNase free water to 
a final volume of 40 µl and stored at -200C until further use.  
 
 2.2.9   Primer design  
 
For analysis of gene expression by RT qPCR, primer pairs were designed by using reference 
sequences of respective genes taken from GeneBank 
(http://www.ncbi.nlm.nih.gov/entrez/query.fcgi). The length of primers was set between 17 
and 27 bp with an optimum length of 20 bp. The melting temperature was established 
between 57°C to 63°C. NCBI BLAST algorithm was used to check alignment of all primers 
sequences against the corresponding reference sequences [97].  
 
Table 2. Reference sequences of CRPV oncogenes used for primer designs taken from 





Reference Sequence (NCBI ref. #) 
 
 SE6 [Kappapapillomavirus 2] 
NP_077106.1 
LE6 [Kappapapillomavirus 2] 
NP_077104.1 
E7 [Kappapapillomavirus 2] 
 
NP_077107.1 
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 2.2.10   Quantitative polymerase chain reaction (qPCR) assay 
 
Real time quantitative PCR analysis was performed by using PowerUpTM Sybr Green Master 
Mix (Applied Biosystems, Darmstadt) according to manufacturer’s protocol. Briefly, both 5′ 
and 3′ primers were diluted with PCR grade water to a final conc. of 10 µmol/L and 1 µl of 
each primer was added to 6 µl PCR mix followed by addition of 2 µl of cDNA. 10 µl of this 
mix was put in each well of  96-well optical plate and wells were sealed with ABI 
MicroAmp™ Optical Adhesive Film and centrifuged briefly to collect the contents and ensure 
that no bubbles inhibit the signal detection. All samples were prepared in triplicates with 5% 
excess for pipetting loss. QuantStudioTM 5 system (Thermo Fisher Scientific) was used for 
quantitative PCR. The following thermal profile was applied: 1 cycle at 50°C for 2 min, at 
95°C for 2 min, 40 cycles at 95°C for 3 s and 60°C for 30 s followed by 4°C hold. Gene 
expression was evaluated in term of fold induction respective to the untreated cellular 
population (control) by 2-ΔΔct method [98].  
Where 
 ct =  Number of amplification cycles required to reach a fixed signal threshold 
Δct = Normalized expression values for each condition ( untreated or treated) 
ΔΔct = Direction and the size of the change in gene expression between two conditions.  
The delta-delta-ct value is the logarithm of the ratio of concentrations, also kown as "log 
fold-change". 
Assessment of results was carried out as follows: genes were considered differently 
expressed when their change was greater than ± 2.5 folds with respect to the transcript levels 
of the untreated sample [16]. All experiments were conducted in triplicates. 
 
 2.2.11    In vitro cytotoxicity assay 
 
To estimate the extent of cellular cytotoxicity as a result of using lipopolyplexes, VX2 and 
COS-7 cells were seeded in 96-well plates at a density of 2x103 and 4x103 cells per well 
respectively and transfected with 0.25 µg of plasmid DNA (E7_GFP) by using 
lipopolyplexes and LipofectamineTM2000 using the same protocol as described previously. 
48 h after transfection, plates were washed twice with PBS containing Ca++ and Mg++ 
followed by addition of 200 µl (2 mg/ml) MTT dye per well and plates were incubated for 4 
h to allow formazan formation. 1 % TritonTMX-100 was deployed as a positive control. 
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Untreated cells were used as negative control and wells containing only medium were taken 
as background control. Once formazan crystals were formed depending on the presence of 
viable cells and MTT interaction, medium was removed from the wells and replaced with 
200 µl of DMSO. Plates were incubated on a shaker (KS4000IC, IKA Werke, Staufen, 
Germany) for 30 min at 120 rpm. The absorbance of samples was measured at 570 nm in a 
FLUOStarTM Optima plate reader [99].  
 
 2.2.12   FACS analysis in E7_GFP expressing cells 
 
VX2 and COS-7 cells were transfected with E7_GFP plasmid DNA using lipopolyplexes as 
transfecting reagents and also by LipofectamineTM2000 used as positive control for 
comparison. After 48 h, cells were trypsinized, fixed in 70 % ethanol and stored at 40C. Prior 
to FACS analysis, cells were centrifuged at 300 g for 10 min, ethanol was removed and the 
cell pellet washed twice in PBS. The pellet was dissolved in 500 µl PBS in a FACS tube by 
gently vortexing followed by flow cytometry analysis on (BD LSR II Becton Dickinson, 
Franklin Lakes, New Jersey). Dead cells (debris) were excluded from analysis by deploying 
forward (FSC) and side scatter (SSC) parameters. GFP expression was detected by 
measurement of the fluorescence (argon laser at 530/30 nm fluorescence with a bandpass 
filter at FL1 channel). 
 
 2.2.13   Fluorescence microscopy 
 
COS-7 cells were seeded with a density of 5x103 cells/well and 1x104 cells/well respectively, 
onto sterilized cover slips (24 mm diameter) in 6-well plates and incubated for 24 h prior to 
transfection. Cells were transfected with E7_GFP plasmid DNA as described earlier. After 
48 h, media was removed and cells were washed with cold PBS containing Ca++ and Mg++ 
(pH 7.4) and fixed with 100 % methanol for 10 min at -20°C followed by washing the cells 
in PBS. Lastly, coverslips were mounted on the cells and sealed with transparent nail polish. 
Confocal laser scanning microscopy (Zeiss Axiovert 100 M, Carl Zeiss Microscopy GmbH, 
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 2.3.1   Detection of CRPV E6 and CRPV E7 in VX2 cells 
 
VX2 cells were grown in DMEM/ Ham`s F-12 medium supplemented with 10 % foetal calf 
serum and antibiotics. After 48 h, cells became 80-90 % confluent and harvested to obtain a 
cell pellet for RNA extraction. RNA was prepared by following the protocol mentioned in 
section (2.2.7). RNA concentration was measured with the Nano Drop ND-1000 system 
(peqLab Biotechnologie GmbH) and 1 µg RNA was used to make cDNA following the 
protocol mentioned above (2.2.8). qPCR was done by using especially designed primers for 
rabbit GAPDH, CRPV E6 and CRPV E7. cDNA prepared from RNA derived from rabbit 
skin was used as a negative control. 
 
 2.3.2   Titration of siRNA concentrations for the knockdown of E6 and E7 
 
To determine appropriate concentration of siRNA for the knockdown of CRPV E6 and E7 
oncogenes in VX2 and COS-7 cells, a range of siRNA concentrations (12.5-150 nmol/L) was 
assessed and following concentrations of siRNA were selected for further studies:  
 
Table 3. siRNA concentrations used for knockdown of CRPV E6 and E7 in VX2 and   COS-




Cell Line Concentration of siRNA 





NT (Non target) VX2 50 nmol/L 48 hours lipopolyplexes 
E6 VX2 50 nmol/L 48 hours lipopolyplexes 
E7 VX2 50 nmol/L 48 hours lipopolyplexes 
E6+E7 VX2 25 nmol/L+25 nmol/L 48 hours lipopolyplexes 
NT (Non target) COS-7 150 nmol/L 48 hours lipopolyplexes 
E6 COS-7 150 nmol/L 48 hours lipopolyplexes 
E7 COS-7 100 nmol/L 48 hours lipopolyplexes 
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 2.3.3   Transfection of siRNA loaded lipopolyplexes in VX2 cells 
 
VX2 cells were directly transfected with siRNA containing lipopolyplexes as VX2 cells 
endogenously express E6 and E7 oncogenes. siRNAs for knockdown of CRPV E6 and E7 
oncogenes were used as described in Table 3. After 48 h incubation, cells were trypsinized 
and pellets were saved for qPCR and Western Blot analysis at -80°C. For flow cytometry, 
VX2 cells were fixed in 70 % ethanol as described above in (2.2.6). 
 
2.3.3.1     RT qPCR analysis 
 
After siRNA knockdown, cells were analysed by RT qPCR method as described above in 
(2.2.10). 
 
2.3.3.2      Western blot analysis 
 
Western blot analysis was performed according to the protocol described in (2.4.1.2.2) except 
for using a different primary antibody (mouse monoclonal anti-PCNA sc-56, clone PC-10, 
1:50, Santa Cruz Biotechnology) 
 
2.3.3.3      MTT assay 
 
VX2 cells were seeded in 96 well plates at a density of 2x103 cells per well. After 24 h, the 
medium was removed and replaced with 90 µl of serum free medium along with 10 µl of 
siRNA loaded lipopolyplexes. 8 wells were treated with Non-Target siRNA loaded 
lipopolyplexes, 8 wells with CRPV_E6 siRNA loaded lipopolyplexes and 8 wells with 
CRPV_E7 siRNA loaded lipopolyplexes. All of the above-mentioned siRNAs were used at 
a concentration of 50 nmol/L. After 48 h, the MTT assay was performed as described above. 
 
 2.3.3.4      Phenotype specificity analysis 
  
As observed during initial studies, VX2 cells exhibit two phenotypes in cell culture which 
grow side by side. One phenotype was called large VX2 cells population and the other 
Phenotype was called small VX2 cells population. In order to see if the knockdown of 
CRPV_E6 or CRPV_E7 or both genes simultaneously, affects the phenotype of these cells, 
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VX2 cells were seeded on a 6-well plate at a density of 2x103 cells per well. After 24 h 
incubation, when cells reached 60-70 % confluency, medium was removed and replaced with 
800 µl of serum free DMEM/ HAM’S F-12 medium. One of 6 wells was treated with 200 µl 
of Non-Target small RNA (50 nmol/L) loaded lipopolyplexes, one well with CRPV_E6 
siRNA (50 nmol/L) loaded lipopolyplexes, one with CRPV_E7 siRNA (50 nmol/L) loaded 
lipopolyplexes and one well with both CRPV_E6 siRNA and CRPV_E7 siRNA (25 
nmol/L+25 nmol/L) loaded lipopolyplexes. After 4 h incubation, 1 ml DMEM/ HAM`S F-
12 medium with serum and antibiotics was added to each well. After 48 h incubation, VX2 
cells treated with siRNA loaded lipopolylexes were observed under the microscope and 
images were taken of each well. The phenotypes in each well were quantified with the 
WIMasis image analysis software (Onimagin Technologies SCA, Cordoba, Spain) on the 
basis of branching point count evaluation [100]. 
 
2.3.3.5      Cell cycle analysis by FACS 
 
Cell cycle phase distribution was analysed after Propidium Iodide (PI) staining using flow 
cytometry. 48 h post transfection and knockdown of CRPV E6 and E7 genes, cells were 
harvested followed by washing cells in cold PBS with subsequent fixation 70 % ethanol. For 
flow cytometry assay, cells were washed twice  in PBS, resuspended in PBS containing 50 
µg/ml RNase A (Sigma Aldrich) and incubated for 30 min at 37°C. Afterwards, 50 µl of 
Propidium Iodide  stock solution (1 mg/ml) was added into cells suspension (final 
concentration: 25 µg/µl) to stain the genomic DNA and samples were passed through (BD 
FACS Calibur Flow Cytometer (Becton Dickinson, Heidelberg, Germany). Maximum 
excitation range of fluorescence used for detection of PI bound to DNA was adjusted to 536 
nm, and emission was set to 617 nm whereas 488 nm was optimal for excitation of PI. Three 
independent experiments were carried out for cell cycle analysis of VX2 cells analysing the 
effect of E6 and E7 SiRNA knockdown. Cell cycle stages were calculated by using the 
ModFit LT software for Mac systems. 
 
2.3.3.6      Real time cellular analysis 
 
Cell adhesion to adjacent cells and to basal extracellular matrix (ECM) is the primary 
requirement for the existence and integrity of all multicellular organisms. Trans-membrane 
heterodimeric family of receptors called integrins are responsible for ECM adhesion of cells 
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by controlling numerous cytoskeletal proteins attached to integrin tails, a vast array of 
signaling and scaffolding. Together, these adhesion components recruit a highly complex and 
dynamic system which regulates various cellular mechanisms and functions including cell 
proliferation, survival, differentiation and migration. Disruption in integrin-mediated cell 
adhesion may be the result of various pathological conditions including cardiovascular 
diseases, bleeding disorders and cancer [101-104]. xCELLigence RTCA system monitors 
changes in cell-ECM adhesion quantitatively.   
 
Impedance measurement depends on the extent of cell confluency and is expressed as Cell 
Index (CI). The cell layer growing on and between gold microelectrodes causes disturbance 
in the current flow thus enhancing electrode impedance (resistance to alternating flow of 
current). The magnitude of Cell Index depends upon the number of cells, their size and the 
degree of firmness of cell adhesion to the substrate coating the plates [105]. 
Cell Index = Rn – Rb / Rb 
Rn = electrode/cells Impedance in a well 
Rb = background Impedance in a well with medium alone.  
 
Migration, proliferation and cell-ECM adhesion in untreated and siRNA treated VX2 cells 
were measured with the xCELLigence system (Roche, Mannheim, Germany). E-plate 
(specifically designed for Impedance measurement of cells, Roche, Mannheim, Germany) 
was prepared by adding 150 µl of DMEM/ Ham’s F-12 medium containing serum and 
antibiotics into the wells. Equilibration was achieved by placing the plate into the 
xCELLigence station and base-line electrical resistance was gauged to make certain that all 
connections to the wells were working in appropriate limits. E-plate was taken out and 50 µl 
of VX2 cells suspension was added to each well with a cell density of 4.5x103 cells per well 
and then placed back in xCELLigence station at 37°C for 24 h.  
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Figure 3.  xCELLigence system (A) The system consists of: real-time cell analysis (RTCA) Analyser, 
RTCA SP Station, RTCA Control Unit and single use E-Plate 96. (B) Cell Index values, derived from 
the measured impedances, are continuously displayed with the Software. (C) Cells attaching on the 
top of the electrode increase the impedance. (Modified from www.roch-applied-
science.com/sis/xcelligence/index) 
 
Cell Index was monitored and once VX2 cells started to adhere to the base, E-plate was taken 
out again and cell culture medium was removed and replaced by 175 µl fresh medium and 
25 µl of siRNA (E6 150 nmol/L, E7 150 nmol/L and E6+E6 75+75 nmol/L) loaded 
lipopolyplex solution. The E-plate was placed again in the incubation chamber of 
xCELLigence instrument for continuous real time monitoring of cell proliferation (every 15 
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2.3.3.7      Wound healing assay 
 
VX2 cells were seeded at a density of 1x104 cells per well in a 6-well plate in DMEM/ Ham’s 
F-12 medium containing serum and antibiotics. After 24 h, the medium was replaced with 
900 µl of serum free DMEM/ HAM’S F-12 medium followed by addition of 100 µl siRNA 
loaded lipopolyplexes solution in each well. Non-Target siRNA 50 nmol/L, E6 siRNA 50 
nmol/L, E7 siRNA 50 nmol/L, and E6 siRNA+E7siRNA 25+25 nmol/L).   
After 4 h, 1 ml DMEM/ HAM’S F-12 medium was added 24 h post siRNA transfection, the 
layer of cells was scratched by using a 100 µl sterile pipette tip. Cells were washed with PBS 
to remove dislodged cells; medium was added again and cells were left in incubator under 
standard conditions. After 24 h at three different positions, micrographs were taken to be 
analysed with the WIMasis image analysis software (Onimagin Technologies SCA, Cordoba, 
Spain) and Fiji ImageJ software. The rate of migration was defined as the percentage of 
wound closure area [106].  
 
 2.3.4   Knockdown of CRPV E6 and E7 in VX2 tumor suspension cells 
 
In this experiment VX2 tumor tissue was taken out from tumor bearing cottontail rabbit and 
triturated to a cell suspension. Out of this raw tumor suspension, 10 µl was taken and put in 
a 50 ml sterilized tube containing 36 ml DMEM: F12 medium with 10 % FCS serum and 
antibiotics. This diluted VX2 tumor suspension was passed through a 0.5 mm mesh. 2 ml of 
this cell suspension was added to each well of three 6-well plates. This cell suspension was 
directly subjected to transfection by different concentrations of siRNA targeting CRPV E6 
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 2.4.1   Validation of siRNA localization on the target transcripts transfected 
into a non-CRPV cell line 
 
Target site accessibility is crucial for successful siRNA knockdown. To confirm that siRNAs 
against CRPV E6 and E7 oncogenes have no off-target effects and are suitable for the 
knockdown of these genes, a series of experiments was contrived in which a non-CRPV cell 
line, COS-7 was used. 
 
2.4.1.1      Transient transfection of cloned plasmids in COS-7 cell line 
 
COS-7 cells were seeded on 6-well plates at a density of 1x104 cells per well in DMEM 
medium with 10 % FCS and antibiotics. After 24 h, COS-7 cells became 60-70 % confluent 
and were transfected with 2 µg of CRPV_E6_GFP and CRPV_E7_GFP expressing plasmids, 
separately, using lipopolyplexes as transfecting reagents. After 24 h incubation, fluorescence 
microscopy was performed to evaluate transfection efficiency (confocal laser scanning 
microscope band pass filters of 505–530 nm, Zeiss Axiovert 100 M, Carl Zeiss Microscopy 
GmbH, Jena, Germany). 
 
2.4.1.2      siRNA knockdown of CRPV E6 and CRPV E7 in COS-7 cells 
 
After validation of E6 and E7_GFP gene expression by fluorescence microscopy after 
transfection, COS-7 cells were transfected with CRPV_E6 or CRPV_E7 specific siRNA 
using siRNA loaded lipopolyplexes as described earlier. Non-target siRNA was used as a 
control to account for unspecific effects of siRNA transfection. The moderate concentration 
of siRNA for the knockdown of CRPV_E6 and CRPV_E7 was achieved after titration 
through multiple experiments, as the expression of CRPV_E6 and CRPV_E7 in transiently 
transfected COS-7 cells is much higher than in VX2 cells in which these genes are a part of 
the genome. So, the concentration of siRNA used for the knockdown of CRPV_E6 and 
CRPV_E7 in VX2 cells, was not comparable or relative to the concentration of siRNA, used 
for the knockdown of the same genes in transiently transfected COS-7 cells. In COS-7 cells, 
150 nmol/L siRNA conc was used for CRPV E6 and 100 nmol/L siRNA for CRPV E7 
SiRNA knockdown. Non-Target siRNA was used as a control in the same concentration as 
used for E6/E7 specific knockdown.  Subsequently, cells were trypsinized and pellets were 
saved for RT qPCR and Western Blot assays respectively. For flow cytometry analysis, COS-
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7 cells were fixed in 70 % ethanol as described previously. 
 
2.4.1.2.1 qPCR analysis 
 
RT-qPCR analysis was performed using the same protocol as described previously. GAPDH 
was chosen as house-keeping gene for normalization.  
 
2.4.1.2.2 Western blot analysis 
 
24 h after siRNA transfection, cell pellets were exposed to lysis buffer containing 2 mM 
EDTA, 1 % NP40, 137 mM NaCl, 20 mM TRIS/HCl (pH 8.0), 10 % glycerol along with 
protease and phosphatase inhibitors (Sigma Aldrich). Lysates were mixed using an orbital 
shaker for 1 h at 4 °C and then centrifuged at 12x103 g for 20 min at 4 °C. Supernatant 
containing the whole cellular protein was transferred to a clean tube and protein concentration 
was measured with the Bradford method using a spectrophotometer (Bio-Rad Labs, 
Munchen, Germany). A 12 % sodium dodecyl sulfate acrylamide gel (SDS-PAGE) was used 
for protein separation according to their size. Each lane was loaded with 35 µg whole cells 
lysate. For size comparison, Precision Plus Protein™ Standard (161-0373) from Biorad 
(Hercules, CA, USA) was used as control. Following SDS-PAGE, proteins were transferred 
to nitrocellulose membranes which were   blocked with 3 % milk/PBS for 1 h at room 
temperature and incubated with the primary antibody (mouse monoclonal Anti-GFP, Santa 
Cruz, CA, USA) overnight at 4 °C. Next day, membranes were washed thrice in 3 % 
milk/PBS for 15 min and incubated with an HRP-coupled secondary antibody (mouse-IgGk 
BP-HRP, 1:2000, Santa Cruz, CA, USA) at room temperature for 1 h. Membranes were 
washed thrice again to remove excessive antibody and bands were visualized with the 
enhanced chemiluminescence (ECL) method (Amersham Biosciences, Buckinghamshire, 
UK) on X-ray film (Agfa, Cologne, Germany). 
 
2.4.1.2.3 Flow cytometry analysis 
 
siRNA knockdown of CPRV E6 and E7 in COS-7 cells should also cause a decline in the 
fluorescence expression of GFP which was tagged along with the respective gene. To confirm 
this, GFP expression in COS-7 cells transfected with CRPV_E6 and CRPV_E7 siRNA 
loaded lipopolyplexes of was analysed by flow cytometry. 
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COS-7 cells were fixed in 70 % ethanol as described earlier. Fixed cells were then centrifuged 
at 300 g for 10 min, ethanol was removed, the pellet was washed twice in PBS and resulting 
pellet was dissolved in 500 µl PBS followed by flow cytometry analysis (BD LSR II, Becton 
Dickinson, Franklin Lakes, New Jersey). Dead cells were excluded from analysis using 
forward and side scatter parameters. GFP expression signal was detected by exciting an argon 
laser at fluorescence intensity 530/30 nm. 
 
2.4.1.2.4 Fluorescence microscopy 
 
Change of GFP expression in COS-7 cells after siRNA knockdown with CRPV E6 and E7 
siRNA was evaluated by (Confocal laser scanning microscope, Zeiss Axiovert 100 M, Carl 
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 2.5.1   Course of CRPV E6 and E7 oncogene expressions under cellular stress 
 
Cancer cells exposed to serum starvation ex vivo partially mimic metabolically distressed 
cells trying to adapt to a changed environment in vivo by inducing exaggerated gene 
expression and signal transduction so that the tumor can grow continuously and least 
perturbed. One study shows that the altered protein and phosphoprotein levels caused by 
serum starvation can reflect the adapted tumor phenotype which can provide some targets for 
cancer therapy [107]. Oncogenes may change their gene expression levels in case of stress 
induction. This study is aimed to assess changes in transcript levels of CRPV E6 and E7 
oncogenes in VX2 cells in the presence of different stress induction scenarios. This may give 
us an insight about the importance of E6 and E7 oncogenes for the survival of cancer cells in 
harsh environments and how targeting these oncogenes can contribute to CRPV cancer 
therapy.  
 
   2.5.1.1      Serum Starvation 
 
For serum starvation experiments, VX2 cells were grown in DMEM/ HAM`S F-12 medium, 
without addition of serum or antibiotics. Different experimental designs of serum starvation 
were applied to witness the change in expression of CRPV E6 and E7 in VX2 cells as enlisted 
below: 
 
1) VX2 cells were grown in serum free DMEM/ HAM`S F-12 medium. After three days, 
cells were trypsinized and passaged again in serum free DMEM/ HAM`S F-12 medium. 
Following three days of incubation, cells were harvested and cell pellet was obtained 
for RNA extraction, cDNA preparation and RT qPCR analysis.  
2) VX2 cells were cultured in serum free DMEM/ HAM`S F-12 medium for 24h. 
Afterwards, cells were harvested, passaged again in serum free DMEM/ HAM`S F-12 
medium and left to grow for 24 h followed by passaging again in serum free DMEM/ 
HAM’S F-12 medium. This cycle was repeated for seven days. Each day, after 
trypsinization of VX2 cells, half of the cell suspension was centrifuged and resultant 
cell pellet was stored for RT qPCR analysis, while half of the cell suspension was 
passaged again to serum free DMEM/ HAM’S F-12 medium and incubated for 24 h. 
VX2 cells in normal medium containing serum and antibiotics were passaged in the 
same way for seven days. 
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3) VX2 cells were cultured in serum free DMEM/ HAM`S F-12 medium in four (10 mm) 
petri dishes and incubated for 24 h. Following scenarios of serum starvation were 
applied in this case: 
 
a) VX2 cells were harvested from dish number 1 after 24 h and the cell pellet was 
stored for RNA extraction and subsequent RT qPCR analysis. 
b) VX2 cells were harvested from dish number two after 48 h and the cell pellet was 
stored for RNA extraction and subsequent RT qPCR analysis. 
c) VX2 cells were harvested from dish number three after 1 week without any medium 
change, and the cell pellet was stored for RNA extraction and subsequent RT qPCR 
analysis. 
d) VX2 cells were harvested from dish number four after two weeks without any 
medium change, and the cell pellet was stored for RNA extraction and subsequent 
RT qPCR analysis 
 
4) VX2 cells were cultured in serum free DMEM/ HAM`S F-12 medium and incubated 
for one week without trypsinization. Medium was changed during this period. After 
seven days incubation in fresh serum free medium daily, cells were harvested for RNA 
extraction, cDNA preparation and RT qPCR analysis.  
 
In all of the above conditions applied, after every trypsinization, 1x104 VX2 cells were 
seeded to pass to the next level of serum starvation. No media with serum was used in 
between any of the above-mentioned serum-starved conditions. At the end of every 
experiment of serum starvation, VX2 cells pellet was collected, RNA was extracted, cDNA 
was prepared and RT qPCR analysis was performed. 
 
   2.5.1.2      Exposure to different concentrations of Cisplatin 
 
VX2 cells were seeded in DMEM/ HAM`S F-12 media with 10 % FCS and antibiotics, in 
the usual fashion mentioned previously. After 24 h, when cells reached 50-60 % confluency, 
cells were exposed to different concentrations of cisplatin (0.01, 0.1, 1, 10, 50 and 100 
µmol/L). After 24 h cisplatin exposure, VX2 cells were trypsinized and cell pellets were 
collected for RNA extraction, cDNA preparation and RT qPCR analysis by following the 
protocols described previously. Expression of CRPV oncogenes (either CRPV E6 or CRPV 
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E7 or both) was analysed. 
cDNA prepared from normal VX2 cells grown in DMEM/ HAM`S F-12 medium with serum 
and antibiotics was used as a positive control in all RT qPCR experiments against cisplatin 
treated VX2 cells.  
 
   2.5.1.3      Effect of 4 Gy radiation and 40 µmol/L Olaparib on VX2 Cells 
 
Olaparib is a PARP, poly (ADP-ribose) polymerase, inhibitor which limits DNA repair as a 
result of oxidative stress and is used to sensitize cancer cells to proton radiation [108]. 
Previous studies have shown that Olaparib causes papilloma virus positive HNSCC cell lines 
to become more sensitive for radiation thus increasing vulnerability of these cell lines for 
radiotherapy [109-111]. VX2 cells were exposed to Olaparib (40 µmol/L), which was non- 
cytotoxic and increased sensitivity of VX2 cells towards radiation, followed by radiation (4 
Gy) to observe the change in expression of CRPV E6. 
 
For this study, VX2 cells were grown in DMEM/ HAM`S F-12 medium with serum and 
antibiotics for 24 h. When cells reached 50-60  % confluency, Olaparib (dissolved in DMSO, 
final conc. 40 µmol/L) was added to the medium above cells and incubated for further 24 h. 
Cells were exposed to ionized radiation (4 Gy) using Gamma cell 1000 Elite irradiator 
(Theratronics, Ottawa, Canada) with a 137Cs source. Afterwards, VX2 cells were trypsinized, 
cell pellet was obtained for RNA extraction, cDNA preparation and subsequent RT qPCR 
analysis to check the expression of CRPV E6 oncogene in irradiated VX2 cells compared to 




All experiments were carried out in triplicates and results were shown as mean ± standard 
deviation. Statistical significance differences were analysed by two-tailed Student’s t-test. 
Results were considered significant with a probability p < 0.05. Statistical differences were 
indicated as "*" p < 0.05, "**" p < 0.01, "***" p < 0.001. Graphical representation of results 
was provided by using GraphPad Prism version 5 for Windows, GraphPad Software (La Jolla 
California, USA)
























Liposomes, Polyplexes and Lipopolyplexes 
 
3.1     Physicochemical properties  
 
 
The basic prerequisite for efficient genetic material delivery into the cells is micro-sized, 
marginally cationic and physiologically intact complexes. Hydrodynamic diameter of these 
complexes is primarily their size which is measured in a hydrated, non-spherical state by 
using dynamic light scattering. The measurements for size determination by laser Doppler 
velocimetry was carried out at a neutral pH (7.4) by using 150 mM NaCl in 20 mM HEPES 
buffer as dilution medium in order to mimic physiological in vivo conditions [112].  
 
 3.1.1   Hydrodynamic diameter 
 
Liposomes and complexes were evaluated for hydrodynamic diameter measurement by using 
size by intensity function of dynamic light scattering. In affirmation with former research 
studies, polyplexes exhibited larger hydrodynamic diameter if their N/P ratio was increased 
for both linear and branched PEI because at higher N/P ratio, polyplexes tend to form 
aggregates shortly after complexation [113]. For N/P ratio of 3 to 20, bPEI complex size was 
decreased from 295.9 ± 6.3 nm to 189.5 ± 6.1 nm respectively. In case of lPEI, for N/P ratio 
of 2.5, the size of complex was 208.5 ± 5.5 nm whereas for N/P ratio 22, it was 125.7 ± 8.5 
nm. These size differences however, showed no prominant changes in the diameter of pDNA 
or siRNA containing polyplexes which was in accordance with previous studies [114].  
 
In this study, formulation containing DOPE, DPPC and cholesterol was analysed. Liposomal 
formulation was extruded through a mini extruder in order to achieve homogenous 
unilamellar consistency with reduced size [115]. In order to correlate the size of liposomes 
with the size range of polyplexes (150-180 nm), the liposomal formulation was passed 
through 400 and 200 nm polycarbonate membranes through extrusion process. Hence, a 
monodisperse formulation of liposomes with an average size range of 160-180 nm was 
obtained having PDI (polydispersity index) of 0.1.  
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As higher concentration of DOPE in the formulation makes liposomes more vulnerable to 
aggregate under physiological conditions and hexagonal structure of DOPE is restored after 
some time, a cautious amount of 70 % of DOPE was used which kept its fusogenic properties 
stable [116]. A detailed account of N/P ratios of polyplexes and mass ratios of polyplexes to 
liposomes gave a conclusive idea for requirement of the desired size range of lipopolyplexes. 
As previous studies indicate that for efficient endocytosis and cellular uptake, complexes 
should be of 200 nm or less in size [117], so liposomes were prepared with a size range of 
170-210 nm. 
 
 3.1.2   Zeta Potential 
 
Zeta potential is described as the electro-kinetic potential in colloidal dispersions. It depends 
upon the electrostatic potential surrounding the double layer of a nanoparticle. The ability of 
nanoparticles such as liposomes to permeate biological layers mainly depend upon zeta 
potential. Therefore, zeta potential is a very important factor which affects cellular interaction 
and uptake of complexes. Two of the most essential factors affecting on zeta potential are pH 
and ionic strength. The gene delivery vehicles need to have a weak positive charge for an 
efficient transfection of genetic material into the cells [118, 119]. Because of the presence of 
DOPE, liposomal formulation showed either neutral or negative zeta potential.  
 
For polyplexes preparation, if N/P ratios of both linear and branched PEI were increased, 
zeta potential was also found to be increased, however, in case of branched PEI, zeta potential 
elevated drastically whereas for linear variant of PEI, zeta potential increased only slightly. 
As high cationic charge of PEI is considered responsible for higher cytotoxicity, only N/P 
ratios with a cationic charge less than +30 mV were used [120]. 
 
Various factors effect on the complexation of liposomes with nucleic acids, nanoparticles or 
complexes such as physical interactions, electrostatic combinations, structural 
rearrangements either individually or in combination [121]. Liposomes play a vital part in 
physicochemical characteristics of a formulation along with polyplexes [122]. Liposomes 
showed a highly negative zeta potential which helped a great deal in neutralizing the high 
cationic charge of PEI thus making lipopolyplexes less cytotoxic. 
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Table 4: Physicochemical properties of liposomes, polyplexes and lipopolyplexes. Size and 




Formulation                                     Size (nm) ± SD     Zeta Potential (mV) ± SD    PDI 
Liposomes (mol %) 
DOPE:DPPC:Cholesterol 
(70:15:15) 
174.7 ± 3.3 -30.9 ± 2.0 0.09 
Polyplexes 
Branched PEI (N/P 15) 
Linear PEI (N/P 9.5) 
180.5 ± 11.6 
166.2 ± 8.7 
+ 27.3 ± 4.4 
+ 19.1 ± 2.7 
0.35 
0.24 
Lipopolyplexes with lPEI polyplexes 
DOPE:DPPC:Cholesterol 
(70:15:15) 
201.1 ± 5.9 + 3.7 ± 2.1 0.19 
Lipopolyplexes with bPEI polyplexes 
DOPE:DPPC:Cholesterol 
(70:15:15) 
194.0 ± 17.3 + 9.5 ± 3.7 0.38 
 
 
Size and zeta potential are expressed as a mean ± standard deviation of three independent 
measurements (n=3). As linear PEI polyplexes with N/P ratio 9.5 showed better trasfection 
abilities and found more stable than branched PEI polyplexes with N/P ratio 15 [14], linear 
PEI containing lipopolyplexes were selected for further studies.   
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3.2     Evaluation of transfection efficiency of lipopolyplexes 
 
 
 3.2.1   Flow cytometry analysis 
 
Transfection of  nucleic acids such as plasmid DNA or RNA is achieved by various methods 
involving physical, chemical or biological methods or a combination of  these [123]. Various 
factors influence transfection efficiency, cellular toxicity and the extent of gene expression. 
To measure the impact of these factors on the efficiency of a transfection method or reagent, 
a reliable detection system is required [124]. An emerging trend among sensitivity-based 
assays is the use of reporter proteins for example green fluorescent protein (GFP) or firefly 
Renilla luciferase [125]. Although Luciferase assays are widely used for its sensitivity and 
suitability to determine relative transfection efficiencies of different samples, major 
limitation of this method is the need to lyse the cells therefore no quantification of cellular 
toxicity is possible. GFP reporter assays require the cellular uptake to be visualized by 
fluorescence microscopy which is laborious and subjective [126].  
 
However, flow cytometry presents a suitable alternative to analyse GFP transfection 
efficiency  allowing for quantification of GFP expression in single cells [127]. To measure 
GFP expression by flow cytometry, GFP alone or GFP-fused proteins or co-transfection of 
GFP with candidate gene expressing plasmid is done. All these techniques have their 
drawback such as competitiveness in expression between two plasmids [128].  
 
In this study plasmid was tagged with GFP and its expression was directly analysed by flow 
cytometry after transfection. Expression of CRPV E7_GFP plasmid was measured in two 
cell lines, VX2 and COS-7, by using lipopolyplexes as transfecting reagents. GFP expression 
in both cell lines was compared with non-transfected cells (negative control) and cells 
transfected with Lipofectamine 2000TM (positive control). 
 
 




Figure 4. Flow cytometry analysis of VX2 cells transfected with E7_GFP plasmid A). Non-transfected 
B) Transfected with Lipofectamine 2000TM C) Overlaid histogram, D) Non-transfected E) transfected 




Figure 5. Flow cytometry analysis of COS-7 cells transfected with E7_GFP plasmid A). Non-
transfected B) Transfected with Lipofectamine 2000TM C) Overlaid histogram, D) Non-transfected E) 
transfected with lipopolyplexes, F) Overlaid histogram 





































































Figure 6. Quantitative analysis of GFP expression in COS-7 and VX2 cells 
 




where X(i) = channel or linear value for the ith event and n = number of events [129]. 
 
These results demonstrated that transfection efficiency of lipopolyplexes in VX2 cells and 
the resulting GFP protein expression was moderate whereas in case of COS-7 cells, 
significant GFP expression was observed after flow cytometry analysis exhibiting high 
transfection efficiency of lipopolyplexes.  
 
Commercially available transfection reagent, Lipofectamine 2000TM was used as a positive 
control. In case of VX2 cells, although positive control showed slightly higher transfection 
efficiency than lipopolyplexes but the difference was not significant elucidating the low 
sensitivity of VX2 cells towards transfectability. COS-7 cells on the other hand, showed 
significant transfection sensitivity for lipopolyplexes as well as for positive control. 
Lipopolyplexes showed even better transfection efficiency in COS-7 cells than 
Lipofectamine 2000TM (figure 6).  
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Although Lipofectamine 2000TM showed better transfection in VX2 cells, it was found more 
cytotoxic (figure 8) and also a high-cost product. On contrary, lipopolyplexes exhibited less 
cytotoxicity (figure 8). In addition, lipopolyplexes preparation is cost effective for the 
intended use in a wide scheme of experimentation with numerous transfection trials making 
them the ideal transfection reagents for in-depth assessment of gene therapy approaches.  
 
   3.2.2   RT qPCR analysis 
 
RT qPCR assay is widely used for the quantification of transfection efficiencies [130]. The 
relative quantification assessed by calculating the fold change between two samples allows 
for accurate insight into the efficiency of a transfection system [131].  
 
In order to quantify the transfection efficiency of lipopolyplexes, mRNA expression of 
E7_GFP plasmid in VX2 and COS-7 cells was analysed by RT qPCR. Untransfected VX2 
and COS-7 cells served as a negative control. In case of both cell lines, cells transfected with 
Lipofectamine 2000TM were used as positive control as it has been widely used as a 
transfecting reagent for all cell lines as a non-viral nucleic acid delivery vehicle. 
 
E7 gene is endogenously expressed in VX2 cells, however, in un-transfected VX2 cells, 
expression of E7 gene is 1 (figure 7), this is because of the fact that untreated VX2 cells are 
taken as a control and in qPCR fold change calculation of a gene expression, control is always 
taken as a constant value i.e.1. So, in transfected VX2 cells, fold change above 1 was taken 
as the transfection efficiency by using lipopolyplexes or Lipofectamine 2000TM (positive 
control) as transfecting reagents.  
 
In case of COS-7 cells, E7 gene does not exist endogenously. So untreated COS-7 cells are 
taken as control which is always a constant value for qPCR fold change calculations of a 
gene expression i.e. 1. Any expression of E7 gene above this constant value of control is 
taken as the efficiency of transfection.  
 




Figure 7. Quantification of E7_GFP gene expression in VX2 and COS-7 cells after 
transfection with E7-GFP plasmids using Lipofectamine 2000TM (LF) and lipopolyplexes 
(LPP) 
 
RT qPCR analysis revealed considerable transfection efficiency of lipopolyplexes in VX2 
and COS-7 which are comparable with the transfection efficiency of commercially available 
Lipofectamine 2000TM. This result is in agreement with the results obtained after flow 
cytometry analysis for the assessment of lipopolyplex transfection efficiency. E7_GFP 
expression was calculated by the delta delta Ct method with GAPDH serving as a house-
keeping gene to normalize the expression levels of transfected genes. 
 
 3.2.3   Cytotoxicity assay 
 
The MTT assay was deployed to quantify cell viability and proliferation. The major 
limitation to use most of the commercially available  transfecting reagents is their higher 
cytotoxicity whereas lipopolyplexes show less cellular toxicity and thus considered safer 
[132] than commercially available transfecting reagents such as Lipofectamine 2000TM. To 
evaluate safety of lipopolyplexes as transfecting reagent, MTT dye was added to the cells 
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and the absorbance of formazan crystals, that form in metabolically active cells, was 
measured which is directly proportional to the number of viable cells [133]. 
 
 
Figure 8. Cell viability assay of VX2 and COS-7. Lipofectamine 2000TM was used as positive 
control whereas untreated cells as negative control 
 
For cytotoxicity evaluation, VX2 and COS-7 cells were transfected with E7_GFP pDNA by 
using lipopolyplexes as transfecting reagents whereas Lipofectamine 2000TM as positive 
control for transfecting cells. For all transfections, 1 µg pDNA (E7_GFP) was used. Un-
transfected VX2 and COS-7 cells were used as negative control (blank). 
Percentage cell viability was measured for both cell lines which showed less percentage of 
cell viability when Lipofectamine 2000TM was used as transfecting reagent in contrast to 
lipopolyplexes in both cell lines. Thus, lipopolyplexes were deemed safer transfecting 












siRNA-mediated knockdown in VX2 cells 
 
3.3 Quantification of E6 and E7 gene expression in VX2 cells 
 
 
CRPV E6 and E7 genes expression  was detected and quantified in VX2 cells by calculating 
fold changes analysed by RT qPCR. cDNA prepared from rabbit skin was used as negative 





Figure 9. Detection of CRPV E6 and E7 gene expressions in VX2 cells. GAPDH and RPL32 
were used as house-keeping genes 
 
CRPV E6 and E7 oncogenes were detected in VX2 cells and found in significant quantitative 
range in comparison to negative control and assumed as suitable in vitro imitators of VX2 
tumor physiology in order to be used for gene therapy investigations. 
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3.4 Knockdown of E6 and E7 by siRNA using lipopolyplexes 
 
 
   3.4.1 siRNA Sequences 
 
Three different types of nucleotide compositions for siRNA were selected from genome 
sequences of CRPV E6 and E7 as shown previously. Interestingly, all individual sequences 
of both E6 and E7 oncogenes exhibited almost the same knockdown potential. Same was 
observed when a combination of siRNA sequences was employed, so after initial studies, 
further siRNA transfection experiments were performed by using randomly any of the 
sequences from the stock. 
 
  3.4.2   Titration of CRPV E6 and E7 siRNA concentrations 
 
Previously reported data indicated roles of CRPV E6 and E7 as transforming genes in 
papilloma formation and also addressed the importance of these genes as possible therapeutic 
targets in CRPV induced carcinomas [74]. Downregulation or suppression of either of these 
genes may cause a significant decline in papilloma development. Titration for selection of a 
moderate concentration of siRNA with significant knockdown potential yet minimum 
cytotoxicity is a relevant first step [134]. Keeping that in mind, different concentrations of 
siRNA starting from as low as 12.5 nmol/L were deployed to evaluate their effect on CRPV 
E6 and E7 oncogene downregulation (figure 10).  
 
In all experiments, non-target control siRNA was utilized at the same concentration as target 
E6/E7 specific siRNA. All experiments were performed thrice and the average expression 
was used to calculate the fold change of CRPV E6 or E7 transcripts. The optimal 
concentration for knockdown of CRPV E6 and E7 genes was found to be 50 nmol/L.  
 













































Figure 10. A collective overview of different concentrations of CRPV E6 and E7 siRNA used 
for the downregulation of CRPV E6 and E7 oncogenes. Combinations of CRPV E6 and E7 
siRNA were also deployed  
 
A combination of both siRNAs (E6+E7) in a concentration of 25 nmol/L individually, 
resulted in a dramatically efficient knockdown of both genes. This collaborative effect of 
siRNA (E6+E7) is witnessed because both of these oncogenes work synergistically as 
previously found in rabbits (CRPV) as well as in humans (HPV) [135]. 
 
Another study reported the outcome of CRPV E1, E2, E6 and E7 vaccination, both 
individually and in combination, in rabbits previously injected with CRPV viral DNA at 
specific sites. Papilloma grew in all (100 %) non vaccinated rabbits. Rabbits vaccinated with 
a single gene vaccine were only partially protected against papilloma growth on the 
challenged sites. However, out of four rabbits vaccinated with E1, E2, E6 and E7 
combination vaccine, two rabbits became completely free of papillomas while in the other 
two rabbits, only small papillomas developed at the challenged sites which regressed within 
three weeks. This outcome showed that CRPV oncoproteins, when targeted in combination 
may lead to synergistic therapeutic effects [136].  
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These findings also correlate with our findings which demonstrate that CRPV E6 and E7 
knockdown shows major effects if siRNAs against E6 and E7 oncogenes are used in 
combination. It was also observed that less amount of siRNA is sufficient for the knockdown 
of CRPV E6 and E7 oncogenes if a combination of siRNA is employed.  
 
 3.4.3   RT qPCR analysis of selected siRNA concentration 
 
CRPV E6 and E7 gene knockdown at a concentration of 50nmol/L( individually) or 
25nmol/L (in combination), are depicted in the figures 10 and 11. All experiments were 





Figure 11. RT qPCR analysis showing downregulation of CRPV E6 with E6 siRNA alone 
and as combination of CRPV E6 and E7 siRNA 
 





Figure 12. RT qPCR analysis showing downregulation of CRPV E7 with E7 siRNA 
individually and as combination of CRPV E6 and E7 siRNA 
 
Inhibition of CRPV E6 and E7 gene expression was greater than 90 % as a result of siRNA 
targeting the single gene and even greater than 95 % when targeting both genes.  
A lot of factors influence on siRNA-mediated knockdown of a gene such as the choice of 
siRNA sequence, concentration, transfecting reagent and type of cell line etc. [134]. As this 
is difficult to transfect 100% of selected concentration of siRNA into the cells without 
encountering any loss either due to pipetting or transfection efficiency, a considerable volume 
of siRNA complex from total volume does not reach within the cell, thus we can suggest only 
an approximate concentration of siRNA useable for knockdown of a gene. For VX2 cells, 
after working with various concentrations, a concentration of 50 nmol/L for CRPV E6 and 
E7 oncogenes was found the most suitable for significant downregulation of oncogenes and 
their relative oncoproteins.  
 
   3.4.4   Cell viability analysis 
 
To determine the effect of knockdown of CRPV E6 and E7 oncogenes on the rate of 
proliferation and viability of VX2 cells, MTT viability assay was employed. 
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As previous studies demonstrated the role of CRPV E6 in protecting tumor cells from 
apoptosis and maintaining cancer cell population integrity [137], this is also observed in VX2 
tumor cells. The percentage of viable VX2 cells was reduced considerably after inhibition of 





Figure 13. Cell viability of VX2 cells (MTT) after siRNA-mediated knockdown 
 
Various studies have shown previously that CRPV E6 and E7 oncogenes play a vital role in 
the transformation and anchorage independent growth of tumor cells [138]. siRNA-mediated 
downregulation of these genes certainly puts a halt on the rate of proliferation of CRPV 
positive cells as shown in figure 13.  A combined use of E6 + E7 siRNA decreased 
proliferation rate of VX2 cells which is in accordance with the synergistic effect resulting in 
higher knockdown of these genes on transcript level as exhibited in previous data shown in 
RT qPCR results (figure 11 and 12) 
 
   3.4.5   Western blot analysis 
 
PCNA is used as one of the most reliable proliferation markers in tumors [139]. Western blot 
analysis was carried out to analyse downregulation of PCNA (proliferating cell nuclear 
antigen) which is responsible for regulating the process of DNA replication during 
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proliferation of cells. PCNA protein has a vital role in cellular physiology by taking part in 





Figure 14. Western blot analysis to analyse expression of PCNA in VX2 cells after siRNA 
knockdown by using CRPV_E6, E7 and E6+E7 
 
Since there are no commercially available antibodies for the detection of CRPV E6 and E7, 
the influence of siRNA knockdown on VX2 cells proliferation was indirectly evaluated in 
western blot. Beta actin was used as a reference protein for the normalization of PCNA 
expression. Three individual experiments were carried out and average expression of PCNA 
was calculated. 
 
Significant downregulation of PCNA protein expression was observed in VX2 cells after 
CRPV E6 and E7 siRNA-mediated knockdown (figure 14) which indicated less rate of 
proliferation of cells after siRNA treatment. CRPV E7 knockdown alone showed variable 
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effects on PCNA expression (not statistically significant). Non-target small RNA treated 
VX2 cells were used as a control. Protein bands were quantified on the basis of optical 
density/intensity by ImageJ/Fiji software [141]. Western blot analysis of siRNA (E6+E7) 
treated cells showed prominent decline in PCNA protein levels which suggested significantly 
less proliferation rate due to downregulation of CRPV E6 and E7 oncogenes. These results 
are in accordance with the previous outcomes demonstrated in figure 11, 12 and 13. 
 
   3.4.6   Cell cycle analysis of VX2 cells after CRPV E6 and E7 knockdown 
 
Cell cycle comprises of a combination of a lot of metabolic changes in dividing cells. There 
are four phases of cell cycle: (a) G1 is a postmitotic phase in which cell synthesizes RNA 
and proteins, (b) S phase, DNA doubles, RNA and proteins continue to be produced, (c) G2, 
no new DNA synthesis whereas RNA and proteins still generated (d) mitosis, completion of 
cell division [142].  
 
It has been previously shown that VX2 cells show major distribution of cells in G1 phase 
69.3%, 5.6% in G2 phase and 25.1% in S phase. Time of population doubling was found 
approximately 34.5 hours [83]. In VX2 cells, G1 phase was found to be 53%, G2 phase 5% 
whereas S phase was 42% which suggests G1 as the most prominent phase in these cells 
closely followed by S phase.  
 
This data also affirms VX2 cells as highly proliferative as G1 and S phases constitute mainly 
of reproductive events of the cells and both of these phases cover almost the whole cycle of 
VX2 cells. These results of cell cycle distribution in VX2 cells are in accordance with the 










Figure 15. Cell cycle phases distribution of VX2 cells analysed after treatment with siRNAs: 
CRPV_siE6 50 nmol/L, CRPV_siE7 5 0nmol/L and CRPV_siE6+E7 (25+25) nmol/L 
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Figure 16. Percentage of VX2 cells in G0/G1 phase and S phases post downregulation of 
CRPV oncogenes 
 
Effect of siRNA treatment and resulting downregulation of CRPV E6 and E7 oncogenes 
showed an arrest in S phase which is DNA replication phase while upregulation of G1 phase. 
G2 phase remained least perturbed as a result of siRNA transfection in VX2 cells. A decline 
in S phase shows that division of cells into daughter cells was affected after siRNA 
transfection. This finding is in accordance with previously shown data and suggests a 
decrease in cell proliferation rate of VX2 cells as a result of knockdown of CRPV E6 and E7 
oncogenes, whether used individually or in combination. All experiments were performed in 
triplicates and values shown (figure 16) were calculated as an average of values of all 
experiments for cell cycle analysis.  
 
   3.4.7   Wound healing assay 
 
Previously, it was found that knockdown of E6 and E7 alone or in combination elicits an 
effect on the rate of cell migration in vitro in cervical cancers such as Caski and SiHa cells 
[143]. To evaluate the influence of CRPV E6 and E7 on cell migration in VX2 cells, wound 
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healing assay was performed. Cell migration analysis revealed that 24 h after scratch 





Figure 17. Images 1, 2, 3 and 4 show VX2 cells with scratch induction after 24 hrs, Image 
1:  migration of NT small RNA (control) treated cells, Image 2: cells treated with siE6, Image 
3: siE7 treated cells, Image 4: siE6+E7 treated cells, Image 5 displays an average of %age 
cell-covered area in all the wells after inducing a scratch (at zero time) 




Figure 18. Rate of wound healing after 24 h in VX2 cells previously transfected by siRNA 
against CRPV E6 and E7 genes, individually and in combination 
 
Rate of wound healing showed less movement of VX2 cells towards wound closure as 
compared to VX2 cells treated with non-target siRNA. Downregulation of CRPV E6 and E7 
genes, individually or combined appeared to inhibit cell migration in VX2 cells. All 
experiments were performed thrice and analysed by Imagej/Fiji [141] and Wimasis 
Microscopy Image Analysis software for visual representation.  
 
   3.4.8   Branching morphogenesis microscopy analysis 
 
The basis of branching morphogenesis originates from the ability of epithelial cells or 
endothelial sheaths to remodel themselves into tubular networks which ultimately develops 
into different organs. This phenomena can be observed in vitro when co-culturing epithelial 
cells with fibroblasts [144]. Epithelial branching morphogenesis is a heavily co-ordinated 
and synchronized system which facilitates cell proliferation, cell to cell communication and 
cell matrix interaction which is a prerequisite for organogenesis. Among all characteristics 
that accompany this process, cell to cell communication and cell matrix interaction were 
evaluated in VX2 cells after CRPV E6 and E7 knockdown.  




Figure 19. Microscopic view (20x) of phenotypic differences between VX2 cells without and 
with connected branching points 
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24 h after siRNA treatment, morphology of VX2 cells was observed under the microscope 
and images were captured for subsequent analysis.  
Branching points between VX2 cells treated with siRNA E6, siRNA E7 and their 
combination (siRNA E6+E7) were counted with the Wimasis Microscopy analysis software. 
Nontarget small RNA treated VX2 cells were taken as a control. Results expressed a decrease 





Figure 20. Quantification of phenotypic differences on the basis of number of branching 
points between adjacent VX2 cells after siRNA-mediated oncogenes knockdown 
 
A considerable decline in the number of branching points between adjacent VX2 cells was 
observed after E6 oncogene knockdown. Although branching connection points were less in 
VX2 cells treated with E7 siRNA as compared to control nontarget (NT) siRNA treated cells, 
this effect was less in those cells treated with siRNA E6 alone or siRNA E6+E7. This shows 
that CRPV E6 downregulation affects greatly on cell phenotype and morphology. Moreover, 
rate of cell proliferation decreases drastically after using siRNA combination of E6 and E7 
on VX2 cells, thus fewer branching points were observed between adjacent cells because of 
reduced number of cells. 
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This assay enables us to quantify the number of proliferation rate of cells without exercising 
any kind of lysis or disturbance to the cells and while letting the cells keep growing during 
the investigation of effect of treatment on their phenotype and cell number. This method is 
very simple, convenient and can be used to document the apparent changes in cells treated 
with control and treatment formulations at various time points under microscope. 
 
 3.4.9   Real time cellular analysis 
 
Cellular motility and adhesion are integral mechanisms behind metastasis and rapid tumor 
growth [145]. xCELLigence system is used to monitor live cell viability, proliferation, 
motility, adhesion, migration, invasion, cell number and morphology. It provides label free 
and real-time surveillance of cell viability by tracking the electrical impedance as a readout 
[146]. xCELLigence system prevents hands-on manipulation of cells thus leading to better 
physiologically relevant results. Moreover, labelling or dying of cells for migration and 
invasion assays can lead to changed gene profiles resulting in altered results and to avoid 
this, xCELLigence system provides kinetic analysis by recording entire processes related to 
cells mobility in real-time [147]. 
 
Real time cellular analysis was performed with the xCELLigence system to measure cell 
viability in VX2 cells after siRNA-mediated knockdown of CRPV E6. For real time 
monitoring of cell growth and assessment of cell proliferation at different time points after 
receiving siRNA treatment, VX2 cells were grown for 24 h onto specifically designed E-
plates. The first peak on the electrical impedance graph (figure 21) shows the time point when 
VX2 cells were added into wells of the E-Plate. Second peak represents the time point (24 h 
after addition of cells) when (non-target and E6) siRNA loaded lipopolyplexes were added 
to the cells. VX2 cells were subsequently monitored for 72 h and their proliferation rate was 
documented. Non-target siRNA treated VX2 cells were used as a control.  
 
It was observed that VX2 cells showed a slumped proliferation rate after siRNA transfection 
and this trend persisted for the entire length of electrical impedance recording (72 h). This 
outcome suggested a decrease in the cell number, rate of growth, invasion and motility of 
VX2 cells and thus invariably reduced growth of CRPV positive cells after CRPV E6 gene 
was downregulated because of siRNA-mediated targeting. 




Figure 21. Real time cellular analysis of proliferation rate of VX2 cells after CRPV E6 
knockdown. (A) cells treated with NT control RNA (50 nmol/L) (Each line represents one 
well of a 96 well E-plate). (B) cells treated with siE6 (50 nmol/L) (C) average of proliferation 







Figure 22.  Cell index depicting proliferation rate of VX2 cells post transfection by non-
target siRNA and CRPV E6 siRNA on the basis of TEER measurement 
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Another exceptional method to validate siRNA-mediated downregulation of CRPV 
oncogenes was the direct use of VX2 tumor suspension. VX2 cells taken directly out of VX2 
tumor without being cultured or passaged in vitro for longer durations so that these cells 
possessed all the exact genomic pattern and tumorigenic characteristics that existed within 
VX2 tumor without undergoing any mutations induced as a result of long-term in vitro 
survival of tumor cells. In this study, VX2 tumor cell suspension was directly subjected to 
transfection by different concentrations of siRNA targeting CRPV E6 and E7 by using 
lipopolyplexes as transfecting reagents. RT qPCR analysis was performed on VX2 tumor 
suspension cells post siRNA transfection after a duration of 48 h incubation, targeting CRPV 
E6 and E7 oncogenes. Statistically significant downregulation of CRPV E6 gene was 
observed at 25, 50 and 150 nmol/L siRNA E6 concentrations, where VX2 tumor suspension 





Figure 23. A collective overview of RT qPCR analysis of different concentrations of siRNA 
CRPV_E6 used for the downregulation of CRPV E6 oncogene in VX2 tumor cell suspension 
 




Figure 24. RT qPCR analysis of different concentrations of siRNA CRPV_E7 after 
downregulation of E7 oncogene in VX2 tumor cell suspension  
 
However, in case of different concentrations of siRNA E7 treatment on VX2 tumor 
suspension cells, statistical significance could not be achieved because of varying Ct values 
between three individual experiments although at a concentration 150 nmol/L siRNA E7, 
downregulation of oncogene could be observed (figure 24)  
 
This experiment design was devised only to have a perception about the efficacy of siRNA 
treatment on raw VX2 tumor tissue although it has various limiting factors such as presence 
of cellular debris as a result of VX2 tumor trituration in spite of filtration, combination of 
cancerous and non-cancerous cells in a whole VX2 tissue suspension,  non-ideal condition 
for the cells to overcome adaption/acclimatization shock and thus upregulation or 
downregulation of various cellular pathways etc. Thus, the titration process to find moderate 
siRNA concentration for knockdown of CRPV E6 and E7 genes on VX2 tumor cell 
suspension exhibited mixed character of upregulation and downregulation of these 
oncogenes unlike a clean culture of only VX2 cells in-vitro. 
 
 




Exogenous knockdown of CRPV E6 and E7 oncogenes by siRNA 
loaded   lipopolyplexes 
 
3.6 siRNA-mediated knockdown of CRPV E6 and E7 in pre-
transfected COS-7 cells 
 
 
This series of experiments involving a CRPV negative cell line COS-7, was designed for 
exogenous knockdown of CRPV E6 and E7 oncogenes to create an alternative system if there 
is no available system for endogenous knockdown of in-house genes of CRPV E6 and E7 
and for in vitro investigation of these oncogenes. Here, we could confirm the specificity of 
our previously used siRNAs directed against CRPV E6 and E7 oncogenes. Plasmids 
encoding CRPV E6 and E7 in the context of a GFP-recombinant protein were previously 
generated in our lab. The transfection efficiency of the lipopolyplexes was previously verified 
in COS-7 cells (figure 5 and 7). 
 
Successful transient transfection of the GFP tagged CRPV E6 and E7 encoding plasmids was 
achieved by using low toxicity lipopolyplexes as transfecting reagents. After verification of 
GFP expression, COS-7 cells were re-transfected by siRNAs directed against CRPV E6 and 
E7 and knockdown of these oncogenes was verified by following assays. 
 
 3.6.1   Flow cytometry analysis 
 
Previously, green fluorescent protein (GFP) has been used as a fluorescent reporter to 
quantify gene expression using flow cytometry after performing transfection [148].  
 
In present study, this method has been used to assess the efficiency of siRNA knockdown 
against transiently transfected CRPV E6 and E7 plasmids by measuring GFP fluorescence 
using flow cytometry. siRNA directed against CRPV E6 and E7 was deployed to evaluate 
knockdown on E6 and E7 target genes. COS-7 cells were incubated for 48 h after siRNA 
treatment followed by detection of GFP fluorescence.  






Figure 25. Histograms of flow cytometry assay expressing GFP positive COS-7 cells. (A, B, 
C, D, E and F), COS-7 cells previously transfected by GFP tagged CRPV E6/ E7 plasmids. 
A and D) COS-7 cells re-transfected by 100 and 150 nmol/L Non-target siRNA respectively. 
B and E) COS-7 cells re-transfected by 150 and 100 nmol/L CRPV_E6 and E7 siRNA 
respectively. C) overlaying histogram shows a comparison between COS-7 cells transfected 
with non-target siRNA and CRPV_E6 siRNA. F) overlaying histogram represents COS-7 
cells transfected with non-target siRNA and CRPV_E7 siRNA 
 
FACS analysis demonstrated a decline in GFP fluorescence after siRNA knockdown of 
CRPV E6 (150 nmol/L) and CRPV E7 (100 nmol/L). COS-7 cells treated with non-target 
(NT) siRNA at the same concentration were used as a negative control.  
 




Figure 26. Mean fluorescence intensity in GFP positive COS-7 cells treated with CRPV 
oncogenes specific siRNAs 
 




where X(i) is the channel or linear value for the ith event and n is the number of events 
 
The siRNA concentrations used were far higher than siRNA concentrations used previously 
for the knockdown of E6 and E7 oncogenes in VX2 cells because of the fact that in case of 
COS-7 cells, after transient transfection, the levels of CRPV E6 and E7 transcripts were 
found much higher than the number of endogenous transcripts present in VX2 cells. E6 and 
E7 genes are expressed endogenously in VX2 cells. Moreover, in VX2, CRPV E6 and E7 
genes coexist and synergise each other’s effect so their efficient knockdown occurs at similar 
concentrations of siRNA (50 nmol/L), while in COS-7 cells, these genes are expressed 
exogenously as a result of transient transfection, so both genes do not necessarily 
downregulate at the same concentration of siRNA. 
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 3.6.2   RT qPCR analysis 
 
CRPV E6_GFP and E7_GFP encoding plasmids were transfected in COS-7 cells and GFP 
expression was examined after 24 h by fluorescence microscopy. After expression of GFP 
tagged plasmid was confirmed by fluorescence microscopy, COS-7 cells were transfected 
with siRNA directed against CRPV E6 and E7 at concentrations of 150 nmol/L and 100 




Figure 27. RT qPCR analysis of siRNA CRPV_E6 and E7 at a concentration of 150 and 100 
nmol/L in previously transfected COS-7 cells with CRPV E6 and E7 plasmids 
 
Real time qPCR showed knockdown of previously transfected CRPV E6 and E7 genes in 
COS-7 cells by using siRNA loaded lipopolyplexes. This outcome attests the efficiency of 
siRNA against CRPV oncogenes and eradicates the possibility of abundant off-target effects. 
Ct values of COS-7 cells transfected with CRPV E6_GFP or E7_GFP plasmids range from18 
to 20 cycles which manifest high level of transfection by lipopolyplexes. As identical levels 
of transfection for both types of plasmids (E6 and E7) are not possible to achieve, so siRNA 
concentrations to downregulate respective gene after transient transfection also differ than 
one another i.e. 150 nmol/L for CRPV E6 and 100 nmol/L for CRPV E7.  
Ct values of VX2 cells to express expression levels of CRPV E6 and E7 onocogenes are 
found between 22 to 28 cycles which show lesser number of CRPV E6 and E7 transcripts 
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than those introduced in COS-7 cells exogenously as a result of transient transfection. 
Therefore, siRNA concentration for the knockdown of CRPV oncogenes in VX2 cells is less 
than in COS-7 cells. 
 
 3.6.3   Western blot analysis 
 
CRPV E6 and E7 proteins cannot be directly detected by western blot because of non-
availability of antibodies against these genes commercially. So, following induction of 
downregulation of these proteins, a functional protein analysis was carried out [149] in order 
to see how lower levels of these oncogenes affect different cellular functions of cancer cells 
which are regulated by these oncoproteins (figure 14). 
 
An alternative approach to directly analyse level of these oncoproteins as a result of gene 
knockdown is, to introduce sequence of a tag or label such as GFP into the genes of CRPV 
E6 and E7, transfecting these constructed plasmids into cells and post siRNA treatment using 
antibody against GFP for the detection of tagged protein in western blot as described by 
previous likewise protocols  [150] .  
 
To analyse downregulation of CRPV E6 and E7 proteins in western blot assay, COS-7 cells 
were transfected with GFP tagged plasmid DNA of CRPV E6 and E7 in separate 6 well 
plates. After 24 h incubation followed by confirmation of GFP tagged plasmids uptake under 
a fluorescent microscope, COS-7 cells were re-transfected with siRNA directed against 
CRPV E6 in a concentration of 150 nmol/L and with siRNA against CRPV E7 in a 
concentration of 100 nmol/L (knockdown by using these concentrations of siRNAs was 
previously established by RT qPCR and flow cytometry analysis) in respective 6 well plates.  
 
Western blot analysis was initiated 48 h post siRNA treatment. In order to estimate the level 
of CRPV E6 and E7 proteins in COS-7 after siRNA-mediated knockdown, anti-GFP antibody 
was used as both of these genes were tagged with GFP label. Βeta tubulin was used as a 
house keeping control protein to normalize expression of target proteins.  
 
 






Figure 28.  Western blot analysis of GFP tagged CRPV E7 expression in COS-7 cells as a 
result of CRPV_E7 siRNA transfection. Although, β-tubulin bands of COS-7 cells expressing 
CRPV E6 GFP treated with siRNA can be observed in western blot, however CRPV E6_GFP 
protein bands could not be detected 
 
Western blot analysis revealed lower expression of CRPV E7_GFP protein in COS-7 cells 
(figure 28). However, expression of GFP tagged CRPV E6 protein could not be detected in 
western blot analysis although bands of reference gene (β-tubulin) appeared. In another 
attempt to detect CRPV E6 protein on western blot membrane, CRPV E6 gene was tagged 
with RFP label and cloned plasmid was transfected in COS-7 cells. However, antibody 
against RFP tag did not show any CRPV E6 protein bands in western blot although beta 
tubulin bands again appeared nevertheless. 
 
Unverified antibodies or non-availability of antibodies altogether limits the use of western 
blot assay in a lot of protein detection or quantification studies [151]. This assay shows a 
unique approach in which tagging fluorescent labels with oncoproteins makes the detection 
of oncoproteins possible in western blot even in the absence of a valid antibody. After 
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siRNA- mediated knockdown of CRPV E7 gene, the decreased level of E7_GFP protein 
could be detected by using anti-GFP antibody against GFP tag attached previously to CRPV 
E7 gene. However, by using the same method, CRPV (E6_GFP) protein could not be detected 
because of some unknown reasons. 
 
 3.6.4   Fluorescence microscopy analysis 
 
Spectral microscopy to analyse expression of GFP uptake in cells under an Inverted 
fluorescence microscope is a convenient and effective method for direct assessment of 
transfection of GFP labelled plasmids [152].  
To determine changes in expressions of GFP fluorescence, after treating previously 
transfected COS-7 cells with GFP tagged E6 and E7 plasmids and later treating these cells 
with siRNAs against these oncogenes, GFP expressing COS-7 cells were analysed under an 
inverted fluorescence microscope (Zeiss Axiovert 100 M) attached with a high-intensity 






Figure 29.  Fluorescence microscopy image of GFP expression in COS-7 cells transfected 
by CRPV_E6 _GFP and CRPV_E7_GFP plasmids, followed by knockdown of CRPV E6 and 
E7 genes by CRPV E6 and E7 siRNA whereas non-target was used as control 
Visual inspection of GFP fluorescence exhibited lesser COS-7 cells expressing GFP post 
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CRPV E6 and CRPV E7 siRNA treatments compared to COS-7 cells treated with non-target 
siRNA as evident in figure 29.  
 
 3.6.5   Cytotoxicity analysis  
 
MTT assay is the most extensively used method to analyse cell viability and cellular 
cytotoxicity in a wide range of experiments. This assay determines cells viability by 
evaluating activity of mitochondrial enzymes for example succinate dehydrogenase [153]. In 
this study, cellular cytotoxicity was measured by using MTT dye on COS-7 cells in order to 
witness effect of double transfection. COS-7 cells were first transfected by GFP tagged 
CRPV E6 and E7 plasmids in separate 6-well plates and post 24 h, transfected again by 
siRNA against CRPV E6 and CRPV E7 oncogenes, by using lipopolyplexes as transfecting 
reagents in both transfections. MTT assay was performed as described earlier and absorbance 





Figure 30. Cell viability assay of untreated COS-7 cells, COS-7 cells after being transfected 
by GFP tagged CRPV E6 and E7 plasmids and COS-7 cells after re-transfection with siRNA 
loaded lipopolyplexes  
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MTT assay outcome exhibited percentage of cell viability greater than 85 % in all samples 
which pronounced that lipopolyplexes are safe carriers for the transfer of GFP tagged CRPV 
E6 and E7 plasmids as well as CRPV E6 and E7 siRNA in COS-7 cells. 
 
As COS-7 cells are “transiently” transfected by CRPV oncogenes and subsequently by 
siRNAs targeted against these oncogenes, these CRPV genes do not become a part of COS-
7 genome and thus do not cause changes in intracellular machinery of COS-7 cells. With 
subsequent passages of COS-7 cells, these exogenous genes or siRNA is diluted out and 
finally disappears completely from the cells. So, cytotoxicity profile of lipopolyplexes as 
transfecting reagents in COS-7 cells (figure 30) shows only a slight decline in cell viability 
which is inevitable in case of a transfection process. This marginal bend in cell viability may 
be partially due to GFP which is assumed potentially cytotoxic for the cells [154] and 
partially due to lipopolyplexes, however the overall percentage of viable COS-7 cells is well 




Limiting factors affecting gene therapy of CRPV carcinoma 
 




Tolerance to nutrient-starvation in cancer cells has been observed as a very important aspect 
of tumor development. A proper understanding of mechanisms of nutrient-independent 
growth of cancer cells seems to be essential in cancer therapy and research. In particular, 
aggressively growing tumors are more prone to experience nutrient-depletion because of 
uncontrollable proliferation as their rate of growth surpasses rate of nutrients providence. In 
these tumors, cell death regulatory proteins may be upregulated or downregulated in order to 
lend immunity to cancer cell from starvation induced apoptosis [155].  This study explains 
the relation between harsh environmental conditions and resultant changing gene expression 
profile of CRPV E6 and E7 oncogenes in VX2 carcinoma which is an aggressive and rapidly 
growing tumor. In molecular targeting therapy such as siRNA mediated gene therapy, the 
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dramatic changes in oncogenes expressions can lead to the failure of treatment. This 
oncogene expression profiling of CRPV E6 and E7 under harsh conditions highlight the 
potential limiting factors which can cause the cancer cells to deregulate the usual expression 
of those genes which are responsible for cell survival and proliferation and thus resulting in 
a different response to gene therapy than expected.  
 
Serum starvation or nutrient depletion is experienced by the cancer cells in vivo during 
metastasis, invasion and tumor development as cancer cells require a lot of nutrients which 
can facilitate the rapid proliferation of tumors and when that does not happen, they become 
serum- depletion independent by overexpression or under-expression of various intracellular 
pathways [84].  
 
 3.7.1   Oncogenic profile shift under serum starvation 
 
Various factors such as serum depletion or low nutrient supply can influence upon the 
expression of oncogenes involved in cellular functions and proliferation [156]. Cancer cells 
are capable of overcoming harsh micro-environment by modifications in their cellular 
signalling pathways resulting in alteration in survival-based gene expressions [84].  
 
CRPV transformed VX2 cells express an invasive and resistant phenotype. Evaluation of 
serum-starvation induced effects on the expression of CRPV oncogenes such as E6 and E7 
in VX2 cells may suggest the behavior of these oncogenes to promote cell survival and 
stimulate the cellular escape from nutrient-depletion induced apoptosis.  
 
For this purpose, various serum starvation schemes were designed and applied on VX2 cells 
as described previously with close monitoring of CRPV E6 and E7 expression levels. Gene 
expression was analysed by RT qPCR. 
 
Serum starvation setup (a) 
 
Under serum starvation conditions as described previously in (2.5.1.1) CRPV E6 and E7 
oncogenes exhibited dramatically huge expression levels in this particular experiment and 
their magnitude exceeded VX2 tumor tissue sample which was used as a positive control. In 
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order to affirm the accuracy of the RT qPCR results, three housekeeping genes, GAPDH, 




Figure 31. RT qPCR analysis of E6 and E7 gene expression in VX2 cells grown in normal 
medium (10% FCS) versus serum starved medium. “VX2 cells SS” represent serum-starved 
cells whereas “VX2 cells” illustrate serum-fed cells  
 
This outcome shows that serum-starvation can lead to unexpected changes in transcript levels 
of oncogenes which are essential for cell survival and cancer growth in VX2 cells. 
 
Serum starvation setup (b) 
  
Expression of CRPV E6 gene in VX2 cells grown in normal medium (10% FCS) contrary to 
VX2 cells grown in serum free medium. VX2 cells grown in both growth conditions were 
trypsinized every day and passaged to the same respective medium in which they were 
growing, for a total period of seven days. 





Figure 32. Time course of E6 gene expression in VX2 cells treated with and without serum 
per day for seven days 
 
A daily account of CRPV E6 and E7 expression levels under serum-fed and serum-starved 
conditions of VX2 cells for seven consecutive days has been exhibited (figure 32). It is 
evident that most of the days, CRPV oncogene levels fluctuate mainly under serum-starved 
conditions towards higher end. In case of serum-fed VX2 cells, oncogenes levels fluctuated 
on a single day and remained more or less the same for other six days.  
 
Serum starvation setup (c) 
 
Another scheme to compare expression of CRPV E6 gene levels in serum-fed VX2 cells 
versus serum-starved VX2 cells per day basis and per week basis is shown below (figure 33). 




Figure 33. RT qPCR analysis of E6 gene expression in VX2 cells grown in normal medium 
(10% FCS) and VX2 cells grown in serum free medium for one day, 2 days, one week and 
two weeks respectively 
 
VX2 cells grown in serum-starved medium for two consecutive days and in a separate setting, 
for two consecutive weeks, showed a persistent pattern of elevation of CRPV E6 oncogene 
level. The outcome of this serum-starvation plan is in accordance with the previous schemes 
which unanimously show an upregulation of CRPV oncogenes when VX2 cells experience 
desperate conditions of nutrients-depletion. 
 
Serum starvation setup (d) 
 
CRPV E6 and E7 gene expressions were analysed in VX2 cells grown in serum-fed and 
serum-starved medium for one week and during this period, medium on the cells was changed 
to fresh medium every day (figure 34). 




Figure 34. Course of E6 and E7 gene expressions in VX2 cells during serum starved and 
serum-fed conditions after one week  
 
The data points to serum starvation induced upregulation of CRPV E6 and E7. The survival 
of VX2 cells under serum-starved conditions for a period of seven days points towards 
tolerance of these cells and ultimately resistance towards nutrient-depletion based apoptosis. 
The survival mechanism in full detail is yet unknown but upregulation of CRPV E6 and E7 
certainly plays a role in VX2 cells survival.  
 
   3.7.2   Effect of Cisplatin exposure on VX2 cells 
 
Exposure of chemotherapeutic agents such as cisplatin to cancer cells can exhibit 
upregulation of specific genes such as ABC (ATP-binding cassette) transporter which are 
involved in efflux of toxic substances such as cisplatin [157, 158]. Similarly, human ovarian 
cancer cells cisplatin exposure at a conc. of 40 µmol/L, for as short as 1 h, induced expression 
of ERCC-1 (excision repair cross-complementation group 1) which is involved in nucleotide 
excision repair [159].  
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To evaluate cellular effects of cisplatin on CRPV oncogenes, different concentrations of 




Figure 35. VX2 cells treated with different concentrations of Cisplatin and their effect on the 
expression of CRPV E6 and E7 oncogenes 
 
Gene expressions of CRPV E6 and E7 were found to climb up many folds higher at a 
Cisplatin concentration of 100 µmol/L (figure 35). This data suggests that under extreme 
stress conditions, VX2 carcinoma has a tendency to become equally aggressive and activate 
cell survival pathways by upregulation of oncogenes which are responsible to keep tumor 
alive and proliferative.  
 
At a Cisplatin concentration of 10 µmol/L, VX2 cells showed downregulation of oncogenes 
E6 and E7 (figure 35), which may be due to the fact that this concentration of Cisplatin is not 
too high for the cells to kick start their cellular survival machinery. 
 
This delicacy of oncogenic shift under specific conditions may affect greatly on choosing the 
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   3.7.3   Effect of Radiation and Olaparib on VX2 Cells 
 
Radiation induced transcriptional and translational changes are reported frequently 
depending upon the type of cell line [160].  VX2 cells were exposed to 40 µmol/L Olaparib 
followed by radiation (4Gy) and their effect was monitored for 24 h on CRPV E6 gene 
expression. As exposure to radiation causes DNA damage in cancer cells [161, 162], it could 
optimize the tumor inhibiting effect especially in the presence of radiosensitizers such as 
Olaparib.  
 
RT qPCR analysis was deployed to analyse if there were changes in CRPV E6 expression 





Figure 36. Time course of VX2 cells treated with 40 µmol/L Olaparib followed by radiation 
(4 Gy) and their effect on CRPV E6 expression 
 
Above results of RT qPCR analysis show that exposure of VX2 cells to 40 µmol/L Olaparib 
and treatment with 4 Gy induced overexpression of CRPV E6 at 8 h and 24 h. After radiation 
therapy, cancer cells have an ability to stop cell cycle at specific checkpoints so that they can 
repair DNA damage. If tumor cells succeed in repairing DNA damage, they develop radiation 
resistance and can survive and proliferate [163].  
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Above data shows that after 8 hours to 24 hours, there is upregulation in CRPV E6 level 
which indicates that DNA repair has been achieved by VX2 cells and they started their 
proliferative machinery in order to replicate.  
 
This result suggests that a close check on the expression level of CRPV E6 oncogene can 
reveal a lot of information about the cellular survival and proliferation at the end of a 
therapeutic application in CRPV carcinoma. It can also help to recognize the cell survival 
potential of cancer cells and to choose the best strategy regarding therapeutic window in order 
to eradicate cancer cells. In summary, all the stress inducing experiments including serum 
starvation, Cisplatin exposure and radiation therapy appear to affect CRPV E6 and E7 mRNA 
expression levels. Identification of behavior of oncogenes CRPV E6 and E7, under different 
treatment conditions can lead to effective approach for the treatment of CRPV cancers where 
caution should be maintained to not elicit aggressive upregulation of oncogenes while 
keeping the treatment threshold to the most effective range of therapeutic window.  
 
   3.7.4   Relation between oncogenic expression shift and gene therapy of CRPV 
induced VX2 carcinoma   
 
To discover an in vitro treatment without a deep insight and comprehension of potential risks 
for the failure of its therapeutic application in vivo may cause serious consequences.  
 
siRNA targeting therapy against oncogenes depends on a lot of factors such as expression 
levels of oncogenes, concentration of siRNA, transfection reagent efficiency and cytotoxicity 
etc. If there is too much fluctuation in oncogene expressions, such as in CRPV carcinoma, 
under certain conditions which are not fully known, it may be difficult to adjust siRNA 
concentration and consequently volume of transfection reagent to a level which has least 
cytotoxicity and efficient knockdown. The therapeutic approaches should also be lenient 
enough to ensure a persistent oncogenic expression profile and exert their anticancer effects 
to the maximum.
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4.1     Summary and Outlook 
 
 
The VX2 carcinoma model from the New Zealand white rabbits serves as a suitable model 
system for human head and neck squamous cell carcinoma. Both cancer models share the 
common papilloma virus. HPV and CRPV both possess the oncogenes E2, E6 and E7. This 
thesis deals with one of the most vital fields of molecular targeting therapy, the siRNA 
induced gene silencing. An extensive literature review-based concept of parallel therapeutic 
options for HPV and CRPV induced carcinomas using siRNA has been addressed. 
Transfection of siRNA into cancer cells is very important for the successful RNAi mediated 
knockdown of oncogenes, therefore the pros and cons of using lipopolyplexes for transfecting 
VX2 cells and a model COS-7 cell line have been analysed.   
 
The introduction part of this thesis comprises of an overview of some fundamental aspects 
of development of cancer. A brief insight into carcinogenicity of HPV and CRPV is discussed 
individually as well as together as both carcinomas originate from papilloma virus. 
Functional features of CRPV E6 and E7 oncogenes are described to highlight their role in 
the development of CRPV positive cancers. Certain attributes of these oncogenes which play 
a key role in immortalisation of rabbit keratinocytes or fibroblasts are listed. The importance 
of establishing an in vitro system to investigate the therapeutic options in CRPV induced 
carcinomas is emphasised by discussing limitations involved in evaluation of treatment 
strategies using in vivo models. The mode of action and efficacy of siRNA treatment in curing 
cancers is described by evidence-based research. The method of preparation of 
lipopolyplexes and their role as transfecting reagents for siRNA and plasmid delivery into 
cells is highlighted based on previously published data.  
 
In materials and methods section, the preparation of lipopolyplexes, physicochemical 
properties, transfection efficiency and cytotoxicity evaluation in VX2 and COS-7 cells and 
the analytical methods here for are described. A detailed account of siRNA targeting against 
CRPV E6 and E7 oncogenes in VX2 cells and confirmation of downregulation of these 
oncogenes using various assay techniques is detailed. An analogous knockdown of CRPV 
E6 and E7 was carried out in a non CRPV cell line, COS-7, as an alternative approach, which 
is beneficial since a long-term in vitro culture of CRPV positive VX2 cells is not possible. 
                                                                                                    Part IV: Summary and Outlook                                                    
                                                                                                                                                                                                                                                                                                                                                                                                        
 92 
The in vitro studies on VX2 cells for the knockdown analysis of CRPV E6 and E7 genes was 
the focus of this project. A detailed behaviour of VX2 cells under different stress factors and 
resulting alteration in expression of oncogenes was documented. A novel method using flow 
cytometry was introduced to evaluate downregulation of CRPV E6 and E7 oncogenes in 
stable transfected COS-7 cells with GFP tagged plasmids. This method is a unique and 
precise way to determine knockdown of a gene as a result of siRNA treatment by detection 
of GFP signal alteration in treated and non-treated cells. A parallel study was performed on 
the cell suspension from VX2 tumor and the effect of siRNA treatment on downregulation 
of CRPV E6 and E7 oncogenes was analysed. 
 
The results and discussion part of this thesis deals with the transfection efficiency of 
lipopolyplexes analysed by FACS and RT qPCR assays on VX2 and stable transfected COS-
7 cells. Knockdown of CRPV E6 and E7 oncogenes in VX2 cells has been studied in detail 
and confirmed by RT qPCR, Western Blotting, FACS, MTT assay, Wound healing assay, 
Branching Morphogenesis Microscopy assay and xCELLigence TEER measurement assay. 
All these analytical evaluations showed downregulation of CRPV E6 and E7 oncogenes as a 
result of siRNA loaded lipopolyplex targeting. To get a deeper insight into the extent of 
efficacy of siRNA treatment on VX2 cells, CRPV E6 and E7 knockdown was carried out in 
a cell suspension prepared by trituration of raw VX2 tumor harvested from tumor bearing 
rabbits. siRNA mediated downregulation of CRPV E6 and E7 were analysed by RT qPCR. 
Another group of experimentation was designed by using a non CRPV cell line, COS-7. GFP 
tagged CRPV E6 and E7 plasmids were stably transfected in these cells. After detection of 
expression of GFP, COS-7 cells were transfected by siRNA against these CRPV oncogenes 
and the downregulation was analysed by FACS, RT qPCR, Western Blotting and MTT assay. 
Significant knockdown of CRPV E6 and E7 genes in COS-7 cells was noted which also 
confirmed the efficacy of lipopolyplex based siRNA treatment in exogenous settings. Next, 
the effect of different stress factors on the gene expression of CRPV E6 and E7 genes in VX2 
cells was explored by creating various scenarios of serum starvation, radiation therapy in 
combination with olaparib and by cisplatin treatment. As a result, it has been suggested that 
a non-linear relationship exists between in vitro conditions and oncogene expression in VX2 
cells. This can be taken as a basic cue to regulate cancer cell response to various treatments 
by also taking into consideration exposure to stress conditions in the cells which may alter 
cellular pathways and oncogene expression levels.  
Collectively, this thesis identifies in vitro aspects which may influence the expression of 
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CRPV E6 and E7 oncogenes in CRPV induced carcinomas and knockdown of these genes 
by lipopolyplex based siRNA targeting. Various assays have confirmed the efficacy of 
siRNA against CRPV E6 and E7 oncogenes endogenously as well as exogenously. 
Investigations carried out in this work also confirm the transfection efficacy and safety of 
lipopolyplexes as transfecting reagents with the added benefit of being cost effective as 
compared to commercially available transfecting reagents.  
 
This study can be used to investigate complexities involved in setting the magnitude of an in 
vitro treatment for translating it into an in vivo therapy as cancer cell lines behave in a non-
linear fashion under different situations of therapeutic investigations and resultant stress. This 
prompts the need for a broader investigation of siRNA treatment and related induction of 
exaggerated expression of oncogenes by doing parallel studies on HPV positive cell lines. 
siRNA mediated silencing of CRPV E6 and E7 can be further investigated in vivo to observe 
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 4.2     Zusammenfassung und Ausblick 
 
 
Das VX2-Karzinommodell des neuseeländischen weißen Kaninchens dient als geeignetes 
Modell für das menschliche Plattenepithelkarzinom im Kopf-Hals-Bereich. Als Auslöser der 
Karzinome gelten u.a. Papillomaviren. Papillomaviren wie HPV und CRPV besitzen die 
Onkogene E2, E6 und E7. Die vorliegende Dissertation befasst sich mit einem der 
wichtigsten Bereiche der zielgerichteten Therapie, dem siRNA-induzierten Gen-Silencing. 
Die Erarbeitung eines Konzeptes, auf Basis bestehender Literatur, zur Behandlung von HPV- 
und CRPV-induzierten Karzinomen war Hauptbestandteil der dieser Arbeit. Die 
Transfektion von siRNA in Tumorzellen ist sehr wichtig für den erfolgreichen RNAi-
vermittelten Knock-down der vorhandenen Onkogene. Die ausführliche Diskussion der Vor- 
und Nachteile eines Lipopolyplex vermittelten Gen Knock-downs in VX2- und COS-7-
Zellen ist ebenfalls Gegenstand der hier dargestellten Untersuchungen.    
 
Der einleitende Teil dieser Arbeit enthält einen Überblick über einige grundlegende Aspekte 
der Tumorgenese sowie eine kurze Darstellung der Kanzerogenität der Papillomaviren HPV 
und CRPV. Ebenso werden die funktionellen Eigenschaften der CRPV E6- und E7-
Onkogene beschrieben, um ihre Rolle bei der Entwicklung von CRPV-positiven 
Tumoridentitäten zu verdeutlichen. Bestimmte Eigenschaften dieser Onkogene, welche eine 
Schlüsselrolle bei der Immortalisierung von Kaninchen-Keratinozyten oder -Fibroblasten 
spielen, werden dargestellt und diskutiert. Die Bedeutung der Etablierung eines in-vitro-
Systems zur Untersuchung der therapeutischen Optionen bei CRPV-induzierten Karzinomen 
wird verdeutlicht. Die Wirkungsweise und Wirksamkeit der siRNA-Behandlung bei der 
Heilung von Tumorerkrankungen stellt die Möglichkeiten der evidenzbasierten Forschung 
dar. Die Herstellungsmethode von Lipopolyplexen und ihre Bedeutung als 
Transfektionsreagenzien für die siRNA- und Plasmidabgabe in Zellen ist ebenfalls 
Bestandteil dieses Kapitels. 
 
Der Abschnitt Materialien und Methoden beschreibt die genaue Herstellung von 
Lipopolyplexen, die Messung der physikalisch-chemischen Eigenschaften, die Ermittlung 
der Transfektionseffizienzen und die Zytotoxizitätsbestimmung in VX2- und COS-7-Zellen. 
Eine detaillierte Darstellung der siRNA, die gegen die CRPV E6- und E7-Onkogene in VX2-
Zellen gerichtet ist, und die Bestätigung der Herunterregulierung dieser Onkogene unter 
                                                                                                    Part IV: Summary and Outlook                                                    
                                                                                                                                                                                                                                                                                                                                                                                                        
 95 
Verwendung verschiedener Assay-Techniken ist ebenso Inhalt dieses Abschnitts. Ein Knock-
down der Onkogene CRPV E6 und E7 wurde in einer Nicht-CRPV-Zelllinie, COS-7 als 
Modellzelllinie nachgewiesen. Der Grund für die Entwicklung dieser Modellzelllinie, mit 
stabil transfizierten CRPV E6 und E7, war, dass eine langfristige in-vitro-Kultur von CRPV-
positiven VX2-Zellen nicht realisierbar ist. Die in-vitro-Studien an VX2-Zellen für die 
Knock-down Analyse der CRPV-Gene E6 und E7 standen im Mittelpunkt dieses Projekts. 
Es wurde detailliert das Verhalten von VX2-Zellen unter verschiedenen Stressfaktoren und 
die daraus resultierende Veränderung der Expression von Onkogenen untersucht. Eine neue 
Methode, unter Verwendung der Durchflusszytometrie, konnte etabliert werden um die 
Herunterregulierung der CRPV E6- und E7-Onkogene in stabil transfizierten COS-7-Zellen 
mit GFP-getaggten Plasmiden zu analysieren. Diese Methode ist eine neuartige und äußerst 
präzise Methode zur Bestimmung des Knock-downs eines Gens als Folge einer siRNA-
Behandlung. Es kommt hierbei zu einer GFP-Signalveränderung in behandelten und 
unbehandelten Zellen. Eine Parallelstudie wurde an einer Zellsuspension des VX2-Tumors 
durchgeführt um die Wirkung der siRNA-Behandlung auf die Downregulation der CRPV-
Onkogene E6 und E7 zu charakterisieren.  
 
Der Ergebnis- und Diskussionsteil dieser Arbeit befasst sich mit der Transfektionseffizienz 
von Lipopolyplexen, die man mittels FACS- und RT-qPCR-Assays an VX2 an stabil 
transfizierten COS-7-Zellen analysiert hat. Eine Bestätigung der Knock-downs von CRPV 
E6- und E7-Onkogenen in VX2-Zellen erfolgte mit Hilfe moderner molekularbiologischer 
Arbeitstechniken wie RT-qPCR, Western Blotting, FACS, MTT-Assay, 
Wundheilungsassay, Branching Morphogenesis Microscopy Assay und das xCELLigence 
TEER Measurement Assay. All diese analytischen Auswertungen zeigten eine 
Herunterregulierung der CRPV E6- und E7-Onkogene als Ergebnis der Behandlung mit 
siRNA-beladenen Lipopolyplexen. Um einen tieferen Einblick in das Ausmaß der 
Wirksamkeit der siRNA-Behandlung von VX2-Zellen zu erhalten, wurde der CRPV E6- und 
E7-Knockdown in einer Zellsuspension durchgeführt. Dies fand durch Isolierung der Zellen 
eines VX2-Tumors, von tumortragenden Kaninchen, statt. Die siRNA-vermittelte 
Herunterregulierung von CRPV E6 und E7 wurde  durch RT-qPCR analysiert. 
Weiterführende Experimente wurden an der Modellzelllinie COS-7 durchgeführt.  Die 
stabile Transfektion dieser Modellzellen erfolgte mit GFP-markierten CRPV E6- und E7-
Plasmiden. Nach dem Nachweis der Expression von GFP wurden COS-7-Zellen mit siRNA 
gegen CRPV-Onkogene transfiziert. Eine Analyse des Knock-downs erfolgte mit Hilfe von 
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FACS, RT-qPCR, Western Blotting und MTT-Assay. Der Knock-down CRPV E6- und E7-
Gene in COS-7-Zellen war signifikant und bestätigte auch die Wirksamkeit einer 
Lipopolyplex-vermittelten siRNA-Behandlung. Als nächstes erfolgte die Untersuchung der 
Wirkung verschiedener Stressfaktoren auf die Genexpression der CRPV E6- und E7-Gene in 
VX2-Zellen. Hierbei wurden verschiedene Szenarien wie Serumverhungern, 
Strahlentherapie in Kombination mit Olaparib und durch Cisplatin-Behandlung in die 
Untersuchungen einbezogen. Als Ergebnis wurde vermutet, dass eine nicht-lineare 
Beziehung zwischen in vitro-Bedingungen und der Onkogenexpression in VX2-Zellen 
besteht. Dies kann als ein Anhaltspunkt für die Regulierung von Tumorzellen auf 
verschiedene Behandlungen angesehen werden. Stressbedingungen verursachen bei 
Tumorzellen eine Änderung des Onkogenexpressionsnveaus.  
 
Zusammenfassend behandelt diese Arbeit in-vitro Aspekte, die die Expression der CRPV 
E6- und E7-Onkogene in CRPV-induzierten Karzinomen und den Knock-down dieser Gene 
durch Lipopolyplex-basierte siRNA-Theapie beeinflussen können. Verschiedene Assays 
haben die Wirksamkeit der siRNA gegen die CRPV-Onkogene E6 und E7 sowohl endogen 
als auch exogen bestätigt. Die in dieser Arbeit durchgeführten Untersuchungen bestätigen 
auch die Transfektionswirksamkeit und -sicherheit von Lipopolyplexen mit dem zusätzlichen 
Vorteil, dass sie im Vergleich zu kommerziell erhältlichen Transfektionsreagenzien 
kostengünstig sind.  
Diese Studie kann verwendet werden, um die Komplexität zu untersuchen, die mit der 
Umsetzung einer in-vitro Behandlung zu einer in-vivo Therapie einhergeht. Der Grund 
hierfür ist das nicht-lineare Verhalten von Tumorzellen unter verschiedenen therapeutischen 
Untersuchungen und Stressbedingungen. Daraus ergibt sich die Notwendigkeit einer 
breiteren Untersuchung der siRNA-Behandlung und der damit verbundenen Induktion einer 
erhöhten Expression von Onkogenen durch parallele Studien an HPV-positiven Zelllinien. 
Der siRNA-vermittelte Knock-down von CRPV E6 und E7 kann in-vivo weiter untersucht 
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 BSA          Bovine serum albumin 
 
bp Base Pairs 
 
bPEI Branched PEI 
 
CI Cell index 
 
CCD Charged Coupled Device 
 
CLSM Confocal Laser Scanning Microscopy 
 




DDC DOPE, DPPC, Cholesterol 
 












dsiRNA Dicer Substrate Short Interfering Ribonucleic Acid 
ECL Enhanced chemiluminescence 
EDTA Ethylene diaminetetraacetic acid 
EGF Endothelial Growth Factor 
EGFP Enhanced Green Fluorescence Protein 
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FCS Fetal calf serum 
FITC Fluorescein isothiocyanate 





Human Papilloma Virus 
Human Head and Neck Squamous Cell Carcinoma 









MW Molecular, Cellular and Developmental Biology (medium) 
MI Mechanical Index 
mRNA Messenger Ribonucleic Acid 
MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
MW Molecular weight 
NP40 Nonidet P 40 substitute 
PBS Phosphate Buffered Saline 
PCI Photochemical Internalisation 
PDI Polydispersity Index 
pDMAEMA Poly (2-dimethylaminoethyl methacrylate) 
pDNA Plasmid Deoxyribonucleic Acid 
PAGE Polyacrylamide gel electrophoresis 
PBS Phosphate buffered saline 
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RISC Ribonucleic Acid Induced Silencing Complex 
RLU Relative Luminescence Units 
RNA Ribonucleic Acid 
SiRNA Ribonucleic Acid Interference 
rpm Revolutions per minute 
RT Room Temperature 
SD Standard Deviation 
SDS Sodium-Dodecyl-Sulphate 
SEM Scanning Electron Microscope 
siCtrl Control Short Interfering Ribonucleic Acid 
siRNA Short Interfering Ribonucleic Acid 
SOC Super Optimal Broth with Catabolite Repression 
TBE Tris(hydroxymethyl)aminomethane/Borate/ 
Ethylenediaminetetraacetic acid 
TEER Transepithelial electrical resistance 
TEMED N, N, N', N'-tetramethyl ethylenediamine 
Tris Tris(hydroxymethyl)aminomethane 
UEGT Ultrasound Enhanced Gene Transfer 
VEGF Vascular Endothelial Growth Factor 
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